era edta
LEADING EUROPEAN NEPHROLOGY

Deutsche Gesellschaft für Nephrologie

58TH ERA-EDTA CONGRESS

FULLY VIRTUAL

JUNE 5-8, 2021



Final Programme

Congress Information

Please click on the links below to see the content.

Congress Website

Welcome Address

ERA-EDTA Council Members

DGfN Council Members

Congress Scientific Committee

Paper Selection Committee & Abstracts Reviewers

- Paper Selection Committee
- LBCT Reviewers
- Abstracts Reviewers

General Information

Best Abstracts

- Ten best abstracts
- Eight best abstracts presented by young authors
- Best abstracts presented by young authors

Programme changes: the organisers cannot assume liability for changes in the programme due to external or unforeseen circumstances.

Content and Daily Index

Scientific Programme

Saturday, 05 June 2021	page	5
Sunday, 06 June 2021	page	15
Monday, 07 June 2021	page	39
Tuesday, 08 June 2021	page	63

Industry Sponsored Symposia

Sunday, 06 June 2021	page 69
Monday, 07 June 2021	page 87

era edta
LEADING EUROPEAN NEPHROLOGY

e-seminars

Exclusive Members' benefit:

Hot Topics in Nephrology created by our Working Groups,
EACCME accreditation included.

Free e-seminars series:

• Covid-19 • CKJ Journal Club • SGLT2- inhibitors and CKD •

Stay updated on latest in Nephrology. Join us!



www.era-edta.org/en/e-seminars/

Day at a glance
Saturday, 05 June 2021

CEPD & HANDS-ON COURSES

PRIMARY & SECONDARY GN, VASCULITIS AND AUTOIMMUNE DISEASES	page 6
HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD	page 6
CKD AND BONE MINERAL DISORDERS IN CKD	page 7
HAEMO- AND PERITONEAL DIALYSIS	page 7
HANDS-ON COURSE ON RENAL MOLECULAR PATHOLOGY	page 7
HANDS-ON COURSE ON VASCULAR ACCESS - Part I	page 8
KIDNEY TRANSPLANTATION	page 9
ACUTE KIDNEY INJURY	page 9
ELECTROLYTES AND UROLITHIASIS	page 10
NEPHROPATHOLOGY	page 10
HANDS-ON COURSE ON VASCULAR ACCESS - Part II	page 11

WELCOME CEREMONY + WELCOME LECTURE	page 12

Scientific Programme

PRIMARY & SECONDARY GN, VASCULITIS AND AUTOIMMUNE DISEASES

CEPD 1 — Hall Dublin - 08:45-12:25 (CEST)

Course Chairs: *Rosanna Coppo, Moncalieri, Italy*
Vladimir Tesar, Prague, Czech Republic
Andreas Kronbichler, Innsbruck, Austria

Chairs: *Vladimir Tesar, Prague, Czech Republic*
Jürgen Floege, Aachen, Germany

1. Immune-mediated kidney disease and COVID-19: *Hans Joachim Anders, Munich, Germany*
2. Risk assessment for progression of IgA nephropathy: *Rosanna Coppo, Moncalieri, Italy*
3. Neutrophil extracellular traps in immune-mediated glomerular diseases: *Cees Van Kooten, Leiden, Netherlands*
4. Anti-GBM disease: *Mårten Segelmark, Lund, Sweden*
5. Immune-mediated interstitial nephritis: *Gema Maria Fernandez Juarez, Madrid, Spain*

HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD

CEPD 2 — Hall A8 - 08:45-12:25 (CEST)

Course Chairs: *Francesca Mallamaci, Reggio Calabria, Italy*
Esteban Porrini, La Esperanza, Spain
Amaryllis van Craenenbroeck, Leuven, Belgium

First session

Chairs: *Francesca Mallamaci, Reggio Calabria, Italy*
Amaryllis van Craenenbroeck, Leuven, Belgium

1. Is CV risk in CKD patients amplified by COVID-19?
Lucia Del Vecchio, San Fermo della Battaglia, CO, Italy
2. A death knell for supplemented Vitamin K to Improve Vascular Stiffness in CKD?
Jennifer Lees, Glasgow, United Kingdom
3. Hyperkalemia in the new era of triple ACE/ARB and Finerenone: no more a cause of concern?
José Valdivielso, Lleida, Spain

Second session

Chairs: *Esteban Porrini, La Esperanza, Spain*
Francesco Trevisani, Milan, Italy

1. The role of non-invasive tools for assessing the cardiovascular risk of obese diabetic patients with chronic kidney disease: *Sebastjan Bevc, Maribor, Slovenia*
2. Therapies for slowing the progression of diabetic kidney disease: from renin angiotensin system blockade agents to the SGLT2 era: *Matias Trillini, Ranica, Italy*

Scientific Programme

CKD AND BONE MINERAL DISORDERS IN CKD

CEPD 3 — Hall Budapest - 08:45-12:25 (CEST)

Course Chairs: *Andrzej Jan Wiecek, Katowice, Poland*
Markus Ketteler, Stuttgart, Germany
Hanne Skou Jørgensen, Aarhus, Denmark

CKD-MBD: From controversies in diagnostics to treatment decisions

Chairs: *Andrzej Wiecek, Katowice, Poland*
Markus Ketteler, Stuttgart, Germany

1. Bone biopsy in clinical decision-making: *Ana Carina Ferreria, Queijas, Portugal*
2. Bone turnover markers - clinical utility in CKD: *Hanne Skou Jørgensen, Aarhus, Denmark*
3. Bone imaging and risk assessment in CKD: *Marie-Helene Lafage-Proust, Lyon, France*
4. PTH, a troublesome hormone: *Markus Ketteler, Stuttgart, Germany*

HAEMO- AND PERITONEAL DIALYSIS

CEPD 4 — Hall New York - 08:45-12:25 (CEST)

Course Chairs: *Olof Heimbürger, Stockholm, Sweden*
Andrew Davenport, London, United Kingdom
Aleksandar Jankovic, Belgrade, Serbia

Chairs: *Olof Heimbürger, Stockholm, Sweden*
Andrew Davenport, London, United Kingdom
Aleksandar Jankovic, Belgrade, Serbia

1.Choice of dialysis mode and adapting prescriptions of PD and HD for patients with cirrosis and ascites: *José Jesús Broseta, Barcelona, Spain*

2. Role of bioimpedance in aiding clinical decision on target weight (both for PD and HD)
Marijke Dekker, Rotterdam, Netherlands

3. Rapid bedside testing for the diagnosis of PD peritonitis*: Arsh Jain, London, Canada*

4. How can physicians improve AV fistula patency?
Andrea Remuzzi, Bergamo, Italy

5. Incremental dialysis in PD and HD: *Enric Vilar, Stevenage, United Kingdom*

HANDS-ON COURSE ON RENAL MOLECULAR PATHOLOGY

Hands Course 1 — Hall London - 8:45-12:25 (CEST)

Chairs: *Loreto Gesualdo, Altamura, Italy*
Helen Liapis, Munich, ND, United States of America

Introduction to Molecular Renal Pathology
Laura Barisoni, Durham, NC, United States of America

2. Indications, technical aspects and procedures of renal biopsy: *Loreto Gesualdo, Altamura, Italy*

3. Practical aspects and procedures of renal biopsy: *Michele Rossini, Bari, Italy*

4. Review and discussion of 20 selected cases with virtual microscopy, immunofluorescence and electron microscopy: *Helen Liapis, Munich, ND, United States of America - Surya V. Seshan, New York, NY, United States of America - Jan Ulrich Becker, Cologne, Germany - Fabio Pagni, Monza, Italy*

HANDS-ON COURSE ON VASCULAR ACCESS

Hands Course 2 - Part I — Hall A1 - 8:45-13:00 (CEST)

Ultrasound of arteriovenous fistula

Chairs: *Maurizio Gallieni, Milan, Italy*
Tamara Jemcov, Belgrade, Serbia

1. Introduction: *Maurizio Gallieni, Milan, Italy - Tamara Jemcov, Belgrade, Serbia*

2. How to examine a vascular access: *Maurizio Gallieni, Milan, Italy*

3. Non-maturing arteriovenous fistula: *Tamara Jemcov, Belgrade, Serbia*

4. Venous outflow stenosis: *Monnie Wasse, Chicago, IL, United States of America*

5. Dialysis access associated hand ischaemia: *Nicola Pirozzi, Rome, Italy*

Procedure/Virtual simulation

1. Virtual reality demo. From mapping to surveillance: *José Ibeas, Barcelona, Spain*

2. Vein mapping: *Jernej Pajek, Ljubljana, Slovenia*

3. Stenosis: *José Ibeas, Barcelona, Spain*

4. Thrombosis: *Marius Kusztal, Wrocław, Poland*

5. Discussion

Catheter placement

Chairs: *Kate Stevens, Glasgow, United Kingdom*
Sokratis Stoumpos, Glasgow, United Kingdom

1. Introduction:

2. Central vein stenosis: *Pete Thomson, Glasgow, United Kingdom*

3. Fibrin sheath: *Sokratis Stoumpos, Glasgow, United Kingdom*

4. Kinking and tip position: *Maria Guedes, Coimbra, Portugal*

5. Atrial thrombus: *Carlo Lomonte, Acquaviva delle Fonti, BA, Italy*

Procedure/Virtual simulation

1. Virtual reality demo. Anatomical approach for ultrasound guided cannulation: *José Ibeas, Barcelona, Spain*

2. Non-tunnelled line insertion: *Maurizio Gallieni, Milan, Italy*

3. Tunnelled line insertion: *José Ibeas, Barcelona, Spain*

4. Discussion

Scientific Programme

KIDNEY TRANSPLANTATION

CEPD 5 — Hall A8 - 13:00-16:00 (CEST)

Course chairs: *Daniel Abramowicz, Edegem, Belgium*
Bruno Watschinger, Vienna, Austria
Elisabet van Loon, Leuven, Belgium

Chairs: *Daniel Abramowicz, Edegem, Belgium*
Bruno Watschinger, Vienna, Austria
Elisabet van Loon, Leuven, Belgium

1. Recurrent glomerulonephritis following renal transplantation
Nicolas Maillard, Saint-Etienne, France

2. Have we reached the limit of living donation? *Aisling Courtney, Belfast, United Kingdom*

3. Should we treat osteoporosis, hyperparathyroidism and hypercalcemia after kidney transplantation? *Hege Pihlstrom, Oslo, Norway*

4. Rejection episodes during COVID-19 pandemic: Who to treat? How to treat?
Ilaria Gandolfini, Parma, Italy

5. How close are we to skip kidney biopsy and to diagnose kidney rejection with biomarkers?
Elisabet van Loon, Leuven, Belgium

ACUTE KIDNEY INJURY

CEPD 6 — Hall Budapest - 13:00-16:00 (CEST)

Course Chairs: *Mehmet Sukru Sever, Istanbul, Turkey*
Andreas Kribben, Essen, Germany
Hessel Peters-Sengers, Amsterdam, Netherlands

Chairs: *Mehmet Sukru Sever, Istanbul, Turkey*
Andreas Kribben, Essen, Germany
Hessel Peters-Sengers, Amsterdam, Netherlands

1. AKI in COVID-19 patients: What is new?
Lui G Forni, Worthing, United Kingdom

2. AKI in non-COVID disasters
Mehmet Sukru Sever, Istanbul, Turkey

3. Management of severe AKI in the ICU – the place of RRT?s
Stephane Gaudry, Paris, France

4. AKI in the obstetric clinics: One complication, jeopardizing two lives
Giorgina Piccoli, Le Mans, France

5. Intrinsic renal AKI, but not acute tubular necrosis: So what?
Michael Joannidis, Innsbruck, Austria

Scientific Programme

ELECTROLYTES AND UROLITHIASIS

CEPD 7 — Hall New York - 13:00-16:00 (CEST)

Course Chairs: *Carsten Wagner, Zurich, Switzerland*
Robert John Unwin, London, United Kingdom
Jean-Philippe Bertocchio, Paris, France

Chairs: *Carsten Wagner, Zurich, Switzerland*
Robert John Unwin, London, United Kingdom

1. Vasopressin and renal water handling: *Francesco Trepiccione, Capua, Italy*
2. Calcium and magnesium disorders: *Lucile Figueres, Saint Herblain, France*
3. Hypo- and hyperparathyroidism: *Jean-Philippe Bertocchio, Paris, France*
4. Disorders of phosphate balance: *Sophie de Seigneux, Geneva, Switzerland*
5. Potassium: *Felix Knauf, Berlin, Germany*

NEPHROPATHOLOGY

CEPD 8 — Hall Budapest - 13:00-16:00 (CEST)

Course Chairs: *Jan Ulrich Becker, Cologne, Germany*
Pablo Cannata-Ortiz, Madrid, Spain
Amelie Dendooven, Antwerp, Belgium

Chairs: *Pablo Cannata-Ortiz, Madrid, Spain*
Amelie Dendooven, Antwerp, Belgium

1. ERKNet consensus on obstructive uropathy/renal dysplasia: *Peter Boor, Aachen, Germany*
2. EMA/ESOT consensus redefinition of rejection endpoints in kidney transplantation: *Marion Rabant, Paris, France*
3. FSGS and minimal change glomerulopathy: what can nephropathology contribute? *Francesca Diomedi-Camessei, Rome, Italy*
4. The spectrum of infection-associated glomerulonephritis: *Jan Ulrich Becker, Cologne, Germany*
5. Nephropathology of Covid-19: *Vanesa Bijol, New York, NY, United States of America*

Scientific Programme

HANDS-ON COURSE ON VASCULAR ACCESS

Hands Course 2 - Part II — Hall A1 - 14:00-16:00 (CEST)

Surgery

Chairs: *Karen Stevenson, Glasgow, United Kingdom*
Nick Inston, Birmingham, United Kingdom

1. Introduction:*Karen Stevenson, Glasgow, United Kingdom*
Nick Inston, Birmingham, United Kingdom
2. Percutaneous arteriovenous fistula: *Charmaine Lok, Toronto, Canada*
3. Recirculation: *Karen Stevenson, Glasgow, United Kingdom*
4. Aneurysmal fistula: *David Shemesh, Jerusalem, Israel*
5. Graft thrombosis: *Emma Aitken, Glasgow, United Kingdom*

Procedure/Virtual simulation

1. Arteriovenous fistula elbow:*
2. Arteriovenous fistula wrist: *Jennifer Hanko, Belfast, United Kingdom*
3. Arteriovenous graft: *Matteo Tozzi, Varese, Italy*
4. Discussion

*At the time of finalization of the Final Programme the speaker of the talk had not yet confirmed the participation.

Scientific Programme

WELCOME CEREMONY + WELCOME LECTURE

Hall A3-7 (Plenary) - 17:00-18:15 (CEST)

Welcome words and Presidential address
Markus Ketteler - Congress President



17:00-17:10

Presidential address
Christoph Wanner - ERA-EDTA President



17:10-17:25

Welcome words and Presidential address
Hermann Josef Pavenstädt - DGfN President



17:25-17:30

Welcome words
Anja Karliczek
German Federal Research Minister
Bundesministerin für Bildung und Forschung



Bundesregierung
Laurence Chaperon

17:30-17:35

Diplomas and thanks - *Christoph Wanner*

17:35-17:41

to *Markus Ketteler* - Congress President



to *Giovambattista Capasso* Chairman of the SC



Scientific Programme

Awards (3 categories) - *Christoph Wanner* 17:41-17:51

ERA-EDTA Award for:
Outstanding Clinical Contributions to Nephrology:
David Jayne



ERA-EDTA Award for:
Research Excellence:
Juan Jesus Carrero



The Stanley Shaldon Award 2021

ERA-EDTA Stanley Shaldon Award for:
Young Investigators:
Thimoteus Speer





Intro of Carlo Barbante:
Giovambattista Capasso 17:51-17:54



Welcome Lecture "Too late for 2°C? From the Paris agreement to the climate of tomorrow" by
Carlo Barbante, Venice, Italy 17:54-18:15



era edta

LEADING EUROPEAN NEPHROLOGY

Cook Book

in Collaboration with the National Societies

Let's raise awareness on the importance of healthy eating to enhance renal health. Actively contribute to our Community. Share your recipes.



www.era-edta.org/en/cookbook/

Supported by Dr. Schär with an educational grant

FLAVIS

Kidney-friendly foods, low in protein, made for those with chronic kidney disease.

www.flavis.com

Day at a glance
Sunday, 06 June 2021

COVID-19 PANDEMIC page 16
DIALYSIS: QUALITY OF LIFE page 16

KDIGO CLINICAL PRACTICE GUIDELINE ON DIABETES MANAGEMENT IN CKD page 17
TRANSPLANTATION & NEW TECHNOLOGIES page 17

NEW TREATMENT TARGETS TO HALT CKD PROGRESSION page 18
ERA-EDTA REGISTRY page 18
BASIC SCIENCE IN AKI page 18

BIG DATA & NEPHROLOGY page 19
FUTURE SCENARIOS FOR RENAL DISEASE page 19

HYPERTENSION & OMICS page 20
MODERATED MINI-ORALS 1 page 20

PLENARY LECTURE 1 page 22
DIALYSIS: HEART & VESSELS page 22
LATE BREAKING CLINICAL TRIALS page 22

NEWS IN PERITONEAL DIALYSIS page 23
TRANSLATIONAL RESEARCH IN KIDNEY TRANSPLANT: FROM BENCH TO BEDSIDE page 23

HYPERTENSION TREATMENT IN SPECIAL RENAL POPULATIONS page 24
DIAGNOSIS AND TREATMENT OF RARE DISEASE IN CHILDREN AND ADULT CKD page 24
ANAEMIA: WHAT ELSE? page 24

INTERVENTIONS IN CKD page 25
ELECTROLYTES: RENAL TRANSPORT AND ENDOCRINE CONTROL page 25

FLUID, GFR & CO. page 26
N-PATH PROJECT PRESENTATION page 26

PATHOPHYSIOLOGICAL PATHWAYS IN CKD page 27
EVERYDAY ISSUES IN DIALYSIS page 27

WHAT PROGRESS IN AKI? page 28
NEWS IN GLOMERULONEPHRITIS TREATMENT page 28
NEW NUTRITIONAL TARGETS IN CKD page 28

THE VIRUS AND THE KIDNEY page 29
GENES & KIDNEY page 29

PREECLAMPSIA AND KIDNEY IN 2021 page 30
HOT TOPICS IN NEPHROLOGY page 30

SURVIVING CKD page 31
MODERATED MINI-ORALS 2 page 31

STONES AND BRAINS page 33
SGLT2-INHIBITORS IN CKD WITHOUT DIABETES page 33

PHOSPHATE AND OTHER MINERALS page 34
TRANSPLANTATION: SHORT- AND LONG-TERM OUTCOMES page 34

PREVENTING KIDNEY AGEING page 35
ENDOCANNABINOIDS AND KIDNEY page 35
OUTCOMES IN PD page 35

STOP DIABETES page 36

AVOIDING A CRASH LANDING OF NEPHROLOGY BY CREATING AWARENESS page 37
A LOOK IN THE CRYSTAL BALL: ENVIRONMENT & EDUCATION page 37

Scientific Programme

COVID-19 PANDEMIC

Symposium 3.1 — Hall A3-7 (Plenary) - 08:00-09:30 (CEST)

Chairs: *Robert Unwin, London, United Kingdom*
Tobias Huber, Hamburg, Germany

1. COVID-19 and history - a perspective from the great influenza pandemic of 1918
Robert Unwin, London, United Kingdom

2. COVID-19 in Europe - clinical experience and learnings
Ron Gansevoort, Groningen, Netherlands

3. COVID-19 trials Lessons for the future?
Martin Landray, Oxford, United Kingdom

DIALYSIS: QUALITY OF LIFE

Free Communication Session 28 + Mini Lectures — Hall A1 - 08:00-09:30 (CEST)

Chairs: *Dimitrios Goumenos, Patras, Greece*
Edwina Brown, London, United Kingdom

Mini Lecture

Comprehensive Conservative Care: what doctors say, what patients hear:
Luc Frimat, Vandoeuvre, France

Free communications

Su174
UTILITY OF A SINGLE ITCH-RELATED QUESTION AND THE SKINDEX-10 QUESTIONNAIRE FOR ASSESSING PRURITUS AND PREDICTING HEALTH RELATED QUALITY OF LIFE IN HEMODIALYSIS PATIENTS
Marcelo Lopes, Ann Arbor, MI, United States of America

Su584
LUNG ULTRASOUND-GUIDED ULTRAFILTRATION IN HAEMODIALYSIS PATIENTS REDUCES THE RISK OF DIALYSIS HYPOTENSION
Claudia Torino, Reggio Calabria, Italy

Su1553
HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND SYMPTOM BURDEN BEFORE AND AFTER START OF DIALYSIS IN OLDER PATIENTS
Esther De Rooij, Leiden, Netherlands

Su1763
THE SOCIETAL IMPACT OF DELAYED DIALYSIS INITIATION ASSOCIATED WITH DAPAGLIFLOZIN BASED ON THE RESULTS OF DAPA-CKD
Phil McEwan, Cardiff, United Kingdom

Scientific Programme

KDIGO CLINICAL PRACTICE GUIDELINE ON DIABETES MANAGEMENT IN CKD

Symposium 8.4 — Hall A8 - 08:00-09:30 (CEST)

Chairs: *Elena Zakharova, Moscow, Russia*
Inga Arūnė Bumblytė, Kaunas, Lithuania

1. HbA1c and beyond
Peter Rossing, Gentofte, Denmark

2. Standard-of-care and self-management
Michel Jadoul, Brussels, Belgium

3. Organ protection: the new concept
Megumi Oshima, Kanazawa, Japan

TRANSPLANTATION & NEW TECHNOLOGIES

Free Communication Session 30 + Mini Lectures — Hall Budapest - 08:00-09:30 (CEST)

Chairs: *Marta Crespo, Barcelona, Spain*
Maria C. Haller, Linz, Austria

Mini Lecture

Comprehensive Conservative Care: what doctors say, what patients hear:
Kai-Uwe Eckardt, Erlangen, Germany

Mini Lecture

Kidney allograft fibrosis: what we have learned from latest translational research studies:
Daniel Seron Micas, Palleja, Spain

Free communications

Su560
THE UPTAKE OF PET RADIOTRACER 18 F-FLUORODEOXYGLUCOSE BY THE RENAL ALLOGRAFT SIGNIFICANTLY CORRELATES WITH THE ACUTE BANFF SCORES OF CORTEX INFLAMMATION
François Jouret, Liege, Belgium

Su1091
SURVIVAL BENEFIT OF KIDNEY TRANSPLANTATION COMPARED TO REMAINING ON WAITLIST ACROSS DIFFERENT AGES OF TRANSPLANT CANDIDATES: A RETROSPECTIVE COHORT STUDY USING TARGET TRIAL EMULATION
Maria C. Haller, Linz, Austria

Su1279
MAGNETIC RESONANCE IMAGING TEXTURE ANALYSIS PREDICTS INTERSTITIAL FIBROSIS / TUBULAR ATROPHY IN TRANSPLANTED KIDNEYS: A SINGLE CENTER CROSS-SECTIONAL STUDY
Francesco Fontana, Modena, Italy

Scientific Programme

NEW TREATMENT TARGETS TO HALT CKD PROGRESSION

Symposium 4.1 — Hall Dublin - 08:00-09:30 (CEST)

Chairs: *Carmine Zoccali, Reggio Calabria, Italy*
Mads Hornum, Copenhagen, Denmark

1. SGLT2-inhibition - the new standard? *Maria José Soler, Barcelona, Spain*

2. Non-steroidal MRA - an emerging option? *Christian Rump, Düsseldorf, Germany*

3. Targeting inflammation pathways - the future? *Thimoteus Speer, Homburg, Germany*

ERA-EDTA REGISTRY

Symposium 0.2 — Hall Helsinki - 08:00-09:30 (CEST)

Chairs: *Kitty Jager, Amsterdam, Netherlands*
Ziad Massy, Paris, France

1. International comparison of trends in kidney transplantation rates in Europe:
Rianne Boenink, Amsterdam, Netherlands

2. Uraemic symptoms and uraemic toxins in the EQUAL study: *Ziad Massy, Paris, France*

3. Work status and work ability of patients treated with kidney replacement therapy:
Rianne de Jong, Amsterdam, Netherlands

BASIC SCIENCE IN AKI

Free Communication Session 12 + Mini Lectures — Hall London - 08:00-09:30 (CEST)

Chairs: *Paola Romagnani, Florence, Italy*
Natalia Stepanova, Kyiv, Ukraine

Mini Lecture

Inflammatory cascade in acute kidney injury:
Kengo Furuichi, Kahoku-Gun, Japan
Natalia Stepanova, Kyiv, Ukraine

Free communications

Su185
THE LONG-TERM EFFECTS OF ACUTE KIDNEY INJURY ON INTESTINAL OXALATE-DE-GRADING BACTERIA IN RATS
Natalia Stepanova, Kyiv, Ukraine

Su1066
IRF8 IN CDC1 IS PROTECTIVE IN POST-ISCHEMIC ACUTE KIDNEY INJURY
Li Na, Munich, Germany

Su1317
SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) DETERMINES

OUTCOMES IN CLINICAL AND EXPERIMENTAL SEPTIC ACUTE KIDNEY INJURY
Christian Nusshag, Chicago, IL, United States of America

Su1838
TUBULAR EPITHELIAL CELL POLYPLOIDY IS ESSENTIAL TO SURVIVE AKI BUT IT CONTRIBUTES TO CKD PROGRESSION
Letizia De Chiara, Florence, Italy

BIG DATA & NEPHROLOGY

Free Communication Session 18 + Mini Lectures — Hall New York - 08:00-09:30 (CEST)

Chairs: *Maurizio Nordio, Treviso, Italy*
Lucile Mercadal, Paris, France

Mini Lecture

The analysis of large public databases for study of human disease: the UK Biobank example
Dorothea Nitsch, London, United Kingdom

Free communications

Su462
QUALITY OF LIFE OVER TIME IN OLDER MEN AND WOMEN WITH ADVANCED CKD - RESULTS FROM THE EQUAL STUDY
Nicholas Chesnaye, Amsterdam, Netherlands

Su495
WHEN TO INITIATE DIALYSIS TO REDUCE MORTALITY AND CARDIOVASCULAR EVENTS IN ADVANCED CKD: NATIONWIDE COHORT STUDY
Edouard Fu, Leiden, Netherlands

Su666
CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: A DANGEROUS COMBINATION
Gurbey Ocak, Utrecht, Netherlands

Su1678
USE OF POTENTIALLY NEPHROTOXIC MEDICATIONS IN PERSONS WITH CHRONIC KIDNEY DISEASE: PARALLEL COHORT STUDIES IN SWEDISH AND U.S ROUTINE CARE
Alessandro Bosi, Solna, Sweden

FUTURE SCENARIOS FOR RENAL DISEASE

Symposium 0.6 — Virtual Hall 1 - 08:00-09:30 (CEST)

Chairs: *Peter J Blankestijn, Utrecht, Netherlands*
Jan Galle, Lüdenscheid, Germany

1. Climate changes and nephrology: *Richard Johnson, Aurora, CO, United States Of America*

2. Demographic changes in different part of the world: *Hans Groth, St. Gallen, Switzerland*

3. Planetary health and burden of life style diseases - what saves the planet saves our health: *Peter Stenvinkel, Stockholm, Sweden*

Scientific Programme

HYPERTENSION & OMICS

Free Communication Session 06 + Mini Lectures — Virtual Hall 2 - 08:00-09:30 (CEST)

Chairs: *Mehmet Kanbay, Istanbul, Turkey*
Hermann Josef Pavenstädt, Münster, Germany

Mini Lecture

Sodium: from gut microbiome to inflammation and hypertension: *Nicola Wilck, Berlin, Germany*

Mini Lecture

Fibromuscular dysplasia: much more than a rare disease: *Alexandre Persu, Brussels, Belgium*

Free communications

Su417
PROTEOMIC PROFILING OF GLOMERULI FROM KIDNEYS WITH HYPERTENSIVE NEPHROPATHY REVEALS SIGNATURE OF DISEASE PROGRESSION
Håvard Mikkelsen, Bergen, Norway

Su424
HIGH DIETARY PHOSPHATE INTAKE UND INTRA-CARDIAC SYNTHESIS OF FIBROBLAST GROWTH FACTOR 23 SYNERGISTICALLY WORSEN CARDIAC FUNCTION
Maren Leifheit-Nestler, Hannover, Germany

Su1288
SINGLE CELL SEQUENCING REVEALS TRANSCRIPTIONAL SIGNATURES AND CELL CROSSTALK IN PATIENTS WITH HYPERTENSIVE NEPHROPATHY
Rong tang, Changsha, China

MODERATED MINI-ORALS 1

Moderated Mini-Orals Hall - 09:30-10:45 (CEST)

Chairs: *Roser Torra, Barcelona, Spain*
Paola Romagnani, Florence, Italy

MO001
THE EUROPEAN DRTA REGISTRY: AN INITIAL DATA ANALYSIS
Detlef Bockenhauer, London, United Kingdom

MO005
GENERATION OF NOVEL 3D CO-CULTURE SYSTEMS TO STUDY PODOCYTOPATHIES EX VIVO IN A PERSONALIZED MANNER
Victoria Rose, Erlangen, Germany

MO006
CHANGES IN THE KYNURENINE PATHWAY LEAD TO ALTERATIONS IN NAD BALANCE AND BIOENERGETICS PARAMETERS IN GLOMERULAR CELLS IN VITRO AND CONTRIBUTE TO PROTEINURIA IN A ZEBRAFISH MODEL
Patricia Bolanos-Palmieri, Erlangen, Germany

MO029
CLINICAL CHARACTERISTICS AND PATHOGENIC GENES OF CONGENITAL SOLITARY KID-

NEY WITH REPRODUCTIVE SYSTEM MALFORMATION
Rongrong Hu, Beijing, China

MO243
STUDY ON THE EFFECT AND MECHANISM OF NOVEL REGULATORY T CELL - CD4+CD126LOWFOXP3+ TREG-IMMUNOTHERAPY IN LUPUS NEPHRITIS
Zhenjian Xu, Guangzhou, China

MO247
NOVEL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES REVEAL CHANGED METABOLOMIC PROFILE IN RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Janina Müller-Deile, Erlangen, Germany

MO249
SINGLE-CELL TRANSCRIPTOME OF COVID19 ASSOCIATED IGA NEPHROPATHY
Line Heylen, Genk, Belgium

MO253
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY (LUMINA-1 STUDY) TO EVALUATE THE SAFETY AND EFFICACY OF CCX140 IN SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROISS (FSGS)
Frank Cortazar, Watervliet, NY, United States of America

MO328
ASYMPTOMATIC HYPERURICEMIA ACTS AS ANTIOXIDANT DURING ACUTE KIDNEY INJURY AND DISEASE
Stefanie Steiger, Munich, Germany

MO564
CHRONIC EXPOSURE TO INDOXYL SULFATE CHANGES BONE PROPERTIES AND EXPRESSION OF SIRT2, SIRT3, AND SIRT7 GENES.
Malgorzata Karbowska, Bialystok, Poland

MO588
DECREASED IL-15 PRODUCTION INDUCED BY HYPERPHOSPHATEMIA AS A POSSIBLE MECHANISM OF AGED-RELATED SARCOPENIA.
Elena Alcalde-Estévez, Guadalajara, Spain

MO620
ANTIFIBROTIC EFFECTS OF SGLT2 INHIBITION IN THE KIDNEY AND PROXIMAL TUBULAR CELLS
Dora Balogh, Budapest, Hungary

MO679
EFFECTS OF ALANYL-GLUTAMINE SUPPLEMENTED PD FLUID ON THE PLASMA METABOLOME AND GUT MICROBIOME IN EXPERIMENTAL PD
Jitka Lachova, Vienna, Austria

MO900
ENHANCED EXPRESSION OF THIOREDOXIN-INTERACTING PROTEIN (TXNIP) RESULTS IN REDUCED TRX ACTIVITY AND INCREASED OXIDATIVE DNA-DAMAGE IN PERITONEAL DIALYSIS PATIENTS
Tina Oberacker, Stuttgart, Germany

Scientific Programme

PLENARY LECTURE 1

Hall A3-7 (Plenary) - 10:45-11:30 (CEST)

Chairs: *Christoph Wanner, Würzburg, Germany*
Markus Ketteler, Stuttgart, Germany

Development of novel, mechanism-based therapies for kidney diseases
Anna Greka, Cambridge, MA, United States of America

DIALYSIS: HEART & VESSELS

Free Communication Session 27 — Hall A1 - 11:45-13:15 (CEST)

Chairs: *Francesca Mallamaci, Reggio Calabria, Italy*
José Manuel Valdivielso, Lleida, Spain

Free communications

Su550
PTH INDCUED ENDMT VIA MIR-29A-5P/GSAP/NOTCH1 PATHWAY CONTRIBUTED TO VALVULAR CALCIFICATION IN RATS WITH CKD
Liting Wang, Nanjing, China

Su841
SNF472 ATTENUATES THE PROGRESSION OF FEMORAL ARTERY CALCIFICATION AND RECOVERS LIMB BLOOD PERFUSION AND WALKING ABILITY IN A RAT MODEL OF PERIPHERAL ARTERY DISEASE
Firas Bassissi, Palma, Spain

Su1532
HIGHER MAGNESIUM DIALYSATE CONCENTRATION SIGNIFICANTLY IMPROVE SURVIVAL AND CEREBRAL OUTCOME IN HD-PATIENTS WITH ATRIAL FIBRILLATION: LONG-TERM STUDY ON GERMAN NETWORK DATA
Karl August Brensing, Bonn, Germany

Su1648
GLUCOSE DERIVATIVE INDUCED VASCULOPATHY IN CHILDREN ON PERITONEAL DIALYSIS
Maria Bartosova, Heidelberg, Germany

Su1885
BASELINE AND CORONARY ARTERY CALCIFICATION PROGRESSION MODULATES THE RISK OF DEATH IN INCIDENT TO DIALYSIS PATIENTS
Antonio Bellasi, Bergamo, Italy

LATE BREAKING CLINICAL TRIALS

Symposium 0.1 — Hall A3-7 (Plenary) - 11:45-13:15 (CEST)

Chairs: *Danilo Fliser, Homburg, Germany*
Maria José Soler, Barcelona, Spain

1. Orally administered C5AR inhibitor Avacopan in a randomized, double blind, placebo-control-

led study (ACCOLADE) for treatment of C3 glomerulopathy
Andrew Bomback, New York, NY, United States of America

2. Interim analysis of a phase 2 dose ranging study to investigate the efficacy and safety of Iptacopan in primary IgA nephropathy
Jonathan Barratt, Leicester, United Kingdom

3. Effects of Dapagliflozin on major adverse kidney events in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial
David C. Wheeler, London, United Kingdom

4. A lung ultrasound guided treatment strategy (LUST) in end stage kidney disease patients at high cardiovascular risk: a randomized multicenter trial
Claudia Torino, Reggio Calabria, Italy

NEWS IN PERITONEAL DIALYSIS

Symposium 6.1 — Hall A8 - 11:45-13:15 (CEST)

Chairs: *Vassilios Liakopoulos, Thessaloniki, Greece*
Edwina Brown, London, United Kingdom

1. Growth of peritoneal dialysis post-COVID-19
Edwina Brown, London, United Kingdom

2. Biocompatible solutions and new osmotic agents
Claus Peter Schmitt, Heidelberg, Germany

3. Incremental peritoneal dialysis prescription
Simon Davies, Stoke-on-Trent, United Kingdom

TRANSLATIONAL RESEARCH IN KIDNEY TRANSPLANT: FROM BENCH TO BEDSIDE

Symposium 7.1 — Hall Budapest - 11:40-13:15 (CEST)

Chairs: *Rainer Oberbauer, Vienna, Austria*
Serhan Z. Tuglular, Istanbul, Turkey

1. Genetic diagnostic biomarkers and new predictors of outcomes in kidney transplantation
Maarten Naesens, Leuven, Belgium

2. T-cell exhaustion in kidney transplant recipients
Paolo Cravedi, New York, NY, United States of America

3. Cell-free DNA a valuable tool to monitor acute rejection after kidney transplantation
Kristien Ledeganck, Antwerp, Belgium

Scientific Programme

HYPERTENSION TREATMENT IN SPECIAL RENAL POPULATIONS

Symposium 8.3 — Hall Dublin - 11:45-13:15 (CEST)

Chairs: *Davide Bolignano, Catanzaro, Italy*
Mustafa Arici, Ankara, Turkey

1. Hypertension management in transition from CKD to ESRD
Aldo Peixoto, New Haven, CT, United States of America

2. Hypertension in patients with renal transplantation: current concepts and future directions
J-M Halimi, Tours, France

3. Hypertension in children and adolescents in CKD
Stella Stabouli, Thessaloniki, Greece

DIAGNOSIS AND TREATMENT OF RARE DISEASE IN CHILDREN AND ADULT CKD

Symposium 2.1 — Hall Helsinki - 11:45-13:15 (CEST)

Chairs: *Franz Schaefer, Heidelberg, Germany*
Roser Torra, Barcelona, Spain

1.Treatment of patients with X-linked hypophosphatemia with borusumab: advances and limitations
Farzana Perwad, San Francisco, CA, United States of America

2. Is ADPKD a paediatric disease?
Francesco Emma, Rome, Italy

3. Mendelian randomization reveals causative factors for kidney function impairment
Sehoon Park, Seoul, Korea, Rep. of South THE KOREAN SOCIETY OF NEPHROLOGY

ANAEMIA: WHAT ELSE?

Free Communication Session 19 — Hall London - 11:45-13:15 (CEST)

Chairs: *Lucia del Vecchio, San Fermo della Battaglia, CO, Italy*
Jan Galle, Lüdenscheid, Germany

Free communications

Su249
POOLED EFFICACY AND CARDIOVASCULAR SAFETY RESULTS OF 3 PLACEBO-CONTROLLED AND 1 DARBEPOETIN ALFA-CONTROLLED STUDIES OF ROXADUSTAT FOR TREATMENT OF ANAEMIA IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE
Jonathan Barratt, Leicester, United Kingdom

Su298
THE SHORT-TERM IMPACT OF HIGH DOSE INTRAVENOUS IRON USE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND IRON DEFICIENCY WITHOUT ANAEMIA - A POST-HOC ANALYSIS OF A MULTICENTRE RANDOMIZED CONTROLLED TRIAL
Kassianides Xenophon, Kingston Upon Hull, United Kingdom

Su681
POST-MORTEM HEPATIC AND BONE MARROW IRON CONTENT IN HEMODIALYSIS PA-

TIENTS: A PROSPECTIVE COHORT STUDY
Patricia Carrilho, Amadora, Portugal

Su1028
REGIONAL EFFICACY AND SAFETY RESULTS OF ROXADUSTAT COMPARED WITH PLACEBO OR DARBEPOETIN ALFA IN NON-DIALYSIS-DEPENDENT (NDD) CHRONIC KIDNEY DISEASE (CKD) PATIENTS WITH ANAEMIA
Nada Dimkovic, Belgrade, Serbia

Su1948
ENHANCED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE (HMGCR) MAY CONTRIBUTE TO THE LOWERING OF LDL CHOLESTEROL SEEN WITH ROXADUSTAT IN PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE
Aisha Chow, San Francisco, CA, United States of America

INTERVENTIONS IN CKD

Free Communication Session 07 + Mini Lectures — Hall New York - 11:45-13:15 (CEST)

Chairs: *Martin de Borst, Groningen, Netherlands*
Ewout Hoorn, Rotterdam, Netherlands

Mini Lecture

Potassium and mortality: *Ewout Hoorn, Rotterdam, Netherlands*

Free communications

Su164
SAFETY AND EFFICACY OF PATIROMER FOR HYPERKALAEMIA IN PATIENTS WITH STAGE 1-3A OR STAGE 3B-5 CHRONIC KIDNEY DISEASE: POOLED ANALYSIS OF THE AMETHYST-DN, OPAL-HK AND TOURMALINE TRIALS
Hermann Haller, Hanover, Germany

Su1115
EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL
Iain Macdougall, London, United Kingdom

Su1555
SAFETY OF BARDOXOLONE METHYL IN PEDIATRIC PATIENTS WITH ALPORT SYNDROME IN CARDINAL PHASE 3 TRIAL
Bradley Warady, Kansas City, MO, United States of America

Su2023
AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF INTRAVENOUS DIFELIKEFALIN IN PATIENTS WITH MODERATE-TO-SEVERE CKD-ASSOCIATED PRURITUS UNDERGOING HEMODIALYSIS
Daniel Weiner, Boston, MA, United States of America

ELECTROLYTES: RENAL TRANSPORT AND ENDOCRINE CONTROL

Symposium 1.4 — Virtual Hall 1 - 11:45-13:15 (CEST)

Chairs: *Sebastian Frische, Aarhus, Denmark*
Juliette Hadchouel, Paris, France

Scientific Programme

1. Gender effects on tubular (salt) handling
Alicia McDonough, San Francisco, CA, United States of America

2. Renal potassium sensing and control of blood pressure
Johannes Loffing, Zurich, Switzerland

3. Glucocorticoids and hypertension revisited
Matthew A Bailey, Edinburgh, United Kingdom

FLUID, GFR & CO.

Free Communication Session 15 + Mini Lectures — Virtual Hall 2 - 11:45-13:15 (CEST)

Chairs: *Tilman Drüeke, Villejuif, France*
Lisbet Brandi, Gentofte, Denmark

Mini Lecture

Hydration and CKD: *Neither too much nor too little?*
Sandra Wagner, Paris, France

Free communications

Su422
SALIVARY POTASSIUM FOLLOWS PLASMA POTASSIUM DYNAMICS IN HEMODIALYSIS PATIENTS
Andras Deak, Graz, Austria

Su466
RATIO OF MEASURED GFR TO ESTIMATED GFR MAY PREDICT EARLY DEATH AND REQUIREMENT FOR DIALYSIS
James G. Heaf, Roskilde, Denmark

Su508
PERCENTILES OF NORMAL MEASURED GLOMERULAR FILTRATION RATE BASED ON DATA FROM LIVING KIDNEY DONORS
François Gaillard, Paris, France

Su767
ESTIMATING ALBUMIN TO CREATININE RATIO FROM PROTEIN TO CREATININE RATIO USING SAME DAY MEASUREMENT: VALIDATION OF EQUATION
Guillaume Resimont, Liège, Belgium

Su991
FUNCTIONAL SODIUM MAGNETIC RESONANCE IMAGING OF HUMAN KIDNEY
Sandrine Lemoine, London, Canada

N-PATH PROJECT PRESENTATION

Symposium 0.8 — Hall A3-7 (Plenary) - 13:30-14:30 (CEST)

Chair: Loreto Gesualdo, Bari, Italy

1. Introduction
Loreto Gesualdo, Bari, Italy

2. Module 1 REMAP
Jadranka Buturovic Ponikvar, Ljubljana, Slovenia

3. Module 2 REVAC
Maurizio Gallieni, Milano, Italy

4. Module 3 REMUS
José Ibeas, Barcelona, Spain

5. Module 4 REPED
Dimitrios Goumenos, Patras, Greece

PATHOPHYSIOLOGICAL PATHWAYS IN CKD

Free Communication Session 17 — Hall A1 - 15:00-16:30 (CEST)

Chairs: *Hiddo Lambers Heerspink, Groningen, Netherlands*
Luca De Nicola, Naples, Italy

Free communications

Su757
DICKKOPF-3 (DKK3) LINKS RECIPROCAL LUNG AND KIDNEY INJURY IN MICE AND HUMANS
Stefan Schunk, Saarbrücken, Germany

Su1227
OBESITY AS A CAUSE OF KIDNEY DISEASE - INSIGHTS FROM MENDELIAN RANDOMISATION STUDIES
Xiaoguang Xu, Manchester, United Kingdom

Su1375
DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL
Hiddo Lambers Heerspink, Groningen, Netherlands

Su1482
A RENAL-CARDIO INFLAMMATORY AXIS MEDIATES CARDIAC DYSFUNCTION IN CKD VIA IL-33-ST2: A NOVEL MECHANISM
Alejandro Chade, Jackson, MS, United States of America

Su2291
PREDICTING OUTCOMES IN ANCA ASSOCIATED VASCULITIS: THE COMPLETE SCOTTISH EXPERIENCE
Dominic McGovern, Glasgow, United Kingdom

EVERYDAY ISSUES IN DIALYSIS

Symposium 5.5 — Hall A8 - 15:00-16:30 (CEST)

Chairs: *Carlo Basile, Acquaviva delle Fonti, BA, Italy*
Frank van der Sande, Maastricht, Netherlands

Scientific Programme

1. How to dose haemodialysis: KtV, signs/symptoms, blood pressure, convection volume, something else?
Andrew Davenport, London, United Kingdom

2. How to choose the best sodium, potassium and bicarbonate level for an individual patient?
Christian Combe, Bordeaux, France

3. How to incorporate patient related outcome measures into everyday dialysis care?
Alferso Abrahams, Utrecht, Netherlands

WHAT PROGRESS IN AKI?

Symposium 9.2 — Hall Budapest - 15:00-16:30 (CEST)

Chairs: *Eric Hoste, Gent, Belgium*
Bjorn Meijers, Leuven, Belgium

1. AKI alerting systems, AI, biomarkers and imaging
Nick Selby, Nottingham, *United Kingdom*

2. AKI repair or regeneration: what to target, when and how?
Paola Romagnani, Florence, Italy

3. AKI: long-term consequences
Carmine Zoccali, Reggio Calabria, Italy

NEWS IN GLOMERULONEPHRITIS TREATMENT

Symposium 3.2 — Hall Dublin - 15:00-16:30 (CEST)

Chairs: *Alexander Rosenkranz, Graz, Austria*
Rosanna Coppo, Moncalieri, Italy

1. IgA nephropathy: is immunosuppression needed?
Jürgen Floege, Aachen, Germany

2. Vasculitis and complement inhibition
Vladimir Tesar, Prague, Czech Republic

3. GWAS in glomerular diseases
Adam Levine, London, United Kingdom

NEW NUTRITIONAL TARGETS IN CKD

Symposium 4.6 — Hall Helsinki - 15:00-16:30 (CEST)

Chairs: *Juan Jesus Carrero, Stockholm, Sweden*
Pablo Molina, Valencia, Spain

1. Are low or very low protein diets still useful and attractive treatment in CKD?
Denis Fouque, Lyon, France

2. Ketogenic diet: a new tool to improve renal cyst growth in ADPKD
Thomas Weimbs, Santa Barbara, CA, United States of America

3. Role of kidney proximal tubules to balance nutrient and uremic toxins levels
Rosalinde Masereeuw, Utrecht, Netherlands

THE VIRUS AND THE KIDNEY

Free Communication Session 08 + Mini Lectures — Hall London - 15:00-16:30 (CEST)

Chairs: *Marlies Noordzij, Amsterdam, Netherlands*
Francesca Viazzi, Genoa, Italy

Mini Lecture

New data on transcriptomics and proteomics of COVID 19 in the kidney
Tobias B. Huber, Hamburg, Germany

Free communications

Su1010
COVID-19 IMPACT ON ELDERLY HEMODIALYSIS POPULATION: RESULTS FROM THE SPANISH COVID-19 CKD WORKING GROUP REGISTRY.
Ander Vergara Arana, Barcelona, Spain

Su1459
COVID-19 IN PATIENTS ON KIDNEY REPLACEMENT THERAPY - CLINICAL CHARACTERISTICS AT TRIAGE ASSOCIATED WITH ADMISSION, READMISSION AND SHORT-TERM OUTCOMES
Sandip Mitra, Manchester, United Kingdom,

Su1797
COVID-19 RELATED MORTALITY IN KIDNEY TRANSPLANT AND DIALYSIS PATIENTS. A COMPARATIVE, PROSPECTIVE REGISTRY BASED STUDY.
Alexandre Candellier, Amiens, France

2207
ACID BASE DISORDERS IN COVID-19
Gaetano Alfano, Modena, Italy

GENES & KIDNEY

Free Communication Session 04 + Mini Lectures — Hall New York - 15:00-16:30 (CEST)

Chairs: *Anna Köttgen, Freiburg, Germany*
Olivier Devuyst, Zurich, Switzerland

Mini Lecture

Epigenetic DNA and histone modifications for CKD treatment

Scientific Programme

Alberto Ortiz, Madrid, Spain

Free communications

Su35
DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1
Hadas Shasha-Lavsky, Nahariya, Israel

★ Su677 KIDNEYNETWORK: USING KIDNEY DERIVED GENE EXPRESSION DATA TO PREDICT AND PRIORITIZE NOVEL GENES INVOLVED IN KIDNEY DISEASE
Laura Claus, Utrecht, Netherlands

Su1000
PRIMARY KIDNEY DISEASE IMPACTS OUTCOME IN CKD PREGNANCIES: COMPLICATIONS IN COL4A3-5 RELATED DISEASE (ALPORT SYNDROME) VS OTHER CKD PREGNANCIES
Rozemarijn Snoek, Utrecht, Netherlands

Su1160
INFLUENCE OF GENETIC VARIATION IN SLC7A13/AGT1 IN HUMAN CYSTINURIA
Ria Schönauer, Leipzig, Germany

PREECLAMPSIA AND KIDNEY IN 2021

Symposium 2.3 — Virtual Hall 1 - 15:00-16:30 (CEST)

Chairs: *Giorgina Piccoli, Le Mans, France*
Fadi Fakhouri, Lausanne, Switzerland

1. Endothelial dysfunction and activation in preeclampsia
Elisa Llurba Olivé, Barcelona, Spain

2. Senescence and preeclampsia
Vesna Garovic, Rochester, MN, United States of America

3. Preeclampsia and future renal disease
Giorgina Piccoli, Le Mans, France

HOT TOPICS IN NEPHROLOGY

Symposium 0.3 — Hall A3-7 (Plenary) - 15:00-16:30 (CEST)

Chairs: *Kirsten deGroot, Offenbach, Germany*
Sibylle von Vietinghoff, Bonn, Germany

1. Changes in the landscape of contrast nephropathy
Daniel Kraus, Mainz, Germany

2. The role, use and pathophysiology of the complement system
Hermann Haller, Hannover, Germany

3. New KDIGO guidelines on the management of glomerulonephritis
Jürgen Floege, Aachen, Germany

Scientific Programme

SURVIVING CKD

Free Communication Session 16 + Mini Lectures — Virtual Hall 2 - 15:00-16:30 (CEST)

Chairs: *Martina Guthoff, Tübingen, Germany*
Davide Bolignano, Catanzaro, Italy

Mini Lecture

CKD and prognosis, mortality, hospitalization: *Marcello Tonelli, Alberta, Canada*

Free communications

Su517
THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS
Emilie Zobel, Gentofte, Denmark

Su553
METABOLIC PROFILING AS A MARKER OF CARDIOVASCULAR DISEASE AND ARTERIAL CALCIFICATION IN THE COPENHAGEN CHRONIC KIDNEY DISEASE COHORT
Ida Maria Hjelm Soerensen, Copenhagen, Denmark

Su924
OSTEOPONTIN AND ITS ASSOCIATION WITH ADVERSE EVENTS IN THE GERMAN CHRONIC KIDNEY DISEASE STUDY
Ulla T. Schultheiß, Freiburg, Germany

Su1048
EARLY LIFE FACTORS AND ADULT KIDNEY FUNCTION ESTIMATED BY CYSTATIN C AND CREATININE GLOMERULAR FILTRATION RATE EQUATIONS AND ALBUMINURIA: A SWEDISH COHORT STUDY.
Agne Laucyte-Cibulskiene, Malmo, Sweden

MODERATED MINI-ORALS 2

Moderated Mini-Orals Hall - 16:30-17:45 (CEST)

Chairs: *Emily McQuarrie, Glasgow, United Kingdom*
Edoardo Melilli, L'Hospitalet de Llobregat, Spain

MO123
USE OF RIVAROXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND ADVANCED CHRONIC KIDNEY DISEASE
Sherzod Abdullaev, Tashkent, Uzbekistan

MO124
THE SINGLE-CELL TRANSCRIPTOMIC OF HUMAN IDIOPATHIC MEMBRANOUS NEPHROPATHY
Yong Zhong, Changsha, China

MO126
CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN
Carla Nester, Iowa City, IA, United States of America

Scientific Programme

MO246
ESTIMATING DELAY IN TIME TO ESKD FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY AND FSGS
Kevin Carroll, Staffordshire, United Kingdom

MO442
ACUTE ADVERSE EFFECTS OF LOW POTASSIUM ON HEART AND KIDNEY
Turgay Saritas, Aachen, Germany

MO481
KIDNEY FUNCTION MEASURES AND THE RISK OF CANCER INCIDENCE, CANCER DEATH AND ALL-CAUSE MORTALITY
Jennifer Lees, Glasgow, United Kingdom

MO483
CHA2DS2-VASC SCORE IN PATIENTS WITH EGFR<30 ML/MIN/1.73 M2 AND ATRIAL FIBRILLATION
Ellen Linnea Freese Ballegaard, Copenhagen, Denmark

MO484
ADVERSE OUTCOMES ASSOCIATED WITH ORAL ANTITHROMBOTIC USE IN PATIENTS WITH MODERATE-TO-ADVANCED CHRONIC KIDNEY DISEASE
Solene Laville, Paris, France

MO485
PREVALENCE OF ANALGESICS USE AND ASSOCIATED ADVERSE OUTCOMES IN THE CHRONIC KIDNEY DISEASE POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Emilie Lambourg, London, United Kingdom

MO721
THROMBOTIC EVENTS AFTER COVID-19 INFECTION IN HEMODIALYSIS PATIENTS
Amir Shabaka, Madrid, Spain

MO763
THE VON WILLEBRAND FACTOR IS A KEY PLAYER IN ARTERIOVENOUS FISTULA MATURATION
Suzanne Suzanne Laboyrie, Leiden, Netherlands

MO922
CASUAL FACTORS AND CLINICAL IMPACT OF URINARY TRACT INFECTIONS IN RENAL TRANSPLANTED PATIENTS: AN OBSERVATIONAL RETROSPECTIVE STUDY
Carlo Maria Alfieri, Milan, Italy

MO977
POTENTIAL INTERACTIONS BETWEEN UREMIC TOXINS AND DRUGS: AN APPLICATION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH CALCINEURIN INHIBITORS
Camille André, Amiens, France

MO1006
COMPARISON OF DIFFERENT DEFINITION OF PARTIAL AND COMPLETE REMISSION IN A COHORT OF CHILDREN WITH LUPUS NEPHRITIS
Chiara De Mutiis, Bologna, Italy

Scientific Programme

STONES AND BRAINS

Free Communication Session 01 + Mini Lectures — Hall A1 - 17:00-18:30 (CEST)

Chairs: *Marion Pepin, Paris, France*
Sophie Liabeuf, Amiens, France

Mini Lecture

Chronic Kidney Disease and Neurological Disorders: Uremic Toxins as a piece of the incomplete puzzle
Sophie Liabeuf, Amiens, France

Mini Lecture

Papal renal stone disease: from Saint Peter to St. John Paul II (34-2005)
Natale Gaspare De Santo, Naples, Italy

Free communications

Su1303
ACIDOSIS AND ALKALI THERAPY ARE ASSOCIATED WITH TRANSCRIPTIONAL CHANGES AND ALTERED ABUNDANCE OF GENES INVOLVED IN CELL METABOLISM AND BICARBONATE TRANSPORT IN KIDNEY TRANSPLANT RECIPIENTS
Pedro Henrique Imenez Silva, Zurich, Switzerland

Su1319
HYPERURICEMIA HAS VASOACTIVE EFFECTS IN CHOLESTEROL CRYSTAL-INDUCED ACUTE KIDNEY INJURY
Luying Yang, Munich, Germany

Su1320
SERUM URIC ACID AND KIDNEY DISEASE MEASURES INDIPENDENTLY PREDICT CARDIOVASCULAR AND TOTAL MORTALITY: THE URIC ACID RIGHT HEART HEALTH (URRAH) PROJECT
Francesca Viazzi, Genoa, Italy

SGLT2-INHIBITORS IN CKD WITHOUT DIABETES

Symposium 4.7 — Hall A3-7 (Plenary) - 17:00-18:30 (CEST)

Chairs: *Beatriz Fernandez Fernandez, Madrid, Spain*
Armin Kurtz, Regensburg, Germany

1. How do SGLT2 inhibitors work?
Volker Vallon, San Diego, CA, United States of America

2. What does imaging tell us?
Roland Schmieder, Erlangen, Germany

3. Non-diabetic heart failure and CKD
Faiez Zannad, Nancy, France

Scientific Programme

PHOSPHATE AND OTHER MINERALS

Symposium 1.3 — Hall A8 - 17:00-18:30 (CEST)

Chairs: *Robert Fenton, Aarhus, Denmark*
Marc Vervloet, Overveen, Netherlands

1. Phosphate and vascular calcification: new avenues for treatment
Jakob Voelkl, Linz, Austria

2. Klotho: effects in kidney, heart and brain
Orson Moe, Dallas, TX, United States of America

3. Inhibition of intestinal and renal phosphate transport as new strategy to treat hyperphosphatemia in CKD
Carsten Wagner, Zurich, Switzerland

TRANSPLANTATION: SHORT- AND LONG-TERM OUTCOMES

Free Communication Session 32 + Mini Lectures — Hall Budapest - 17:00-18:30 (CEST)

Chairs: *Maria Pippias, Bristol, United Kingdom*
Amaryllis Van Craenenbroeck, Leuven, Belgium

Mini Lecture

Recurrent glomerulonephritis after kidney transplantation: an update
Piergiorgio Messa, Milan, Italy

Free communications

Su758
IMPACT OF POLYCLONAL ANTI-T-LYMPHOCYTE IMMUNOGLOBULINS ON THE RECURRENCE OF IGA NEPHROPATHY AFTER KIDNEY TRANSPLANTATION: THE PIRAT STUDY
Nicolas Maillard, Saint Etienne, France

Su1980
NON-HLA ANTIBODIES AND EPLET MISMATCHES IN KIDNEY TRANSPLANT RECIPIENTS WITH A HISTOLOGICAL PICTURE OF ANTIBODY-MEDIATED REJECTION WITH AND WITHOUT HLA DONOR-SPECIFIC ANTIBODIES
Laura Llinàs, Barcelona, Spain

Su2085
CHANGES IN PERIPHERAL NK CELLS IN KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT HLA DSA
Laura Llinas, Barcelona, Spain

Su2329
SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS (SGLT2I) SHORT-TERM OUTCOME IN DIABETIC KIDNEY TRANSPLANT RECIPIENTS
Jude Yagan, Kuwait, Kuwait

Scientific Programme

PREVENTING KIDNEY AGEING

Symposium 4.5 — Hall Dublin - 17:00-18:30 (CEST)

Chairs: *Giuseppe Paolisso, Naples, Italy*
Francesco Mattace Raso, Rotterdam, Netherlands

1. The potential influence of the genetic background
Roland Schmitt, Hannover, Germany

2. Non-genetic factors driving kidney ageing
Anette Melk, Hannover, Germany

3. Preserving Klotho expression
Maria Dolores Sanchez-Niño, Madrid, Spain

ENDOCANNABINOIDS AND KIDNEY

Symposium 9.3 — Hall Helsinki - 17:00-18:30 (CEST)

Chairs: *Vincenzo Di Marzo, Quebec City, Canada*
Cristoforo Silvestri, Quebec City, Canada

1. From the endocannabinoid system to the endocannabinoidome and its interactions with the gut microbiome: relevance to kidney physiopathology
Cristoforo Silvestri, Quebec City, Canada

2. Cannabinoid receptor and hepatorenal syndrome
Pal Pacher, Rockville, MD, United States of America

3. The role of cannabinoid signalling in chronic kidney diseases
Gabriella Gruden, Turin, Italy

OUTCOMES IN PD

Free Communication Session 26 + Mini Lectures — Hall London - 17:00-18:30 (CEST)

Chairs: *Wim Van Biesen, Ghent, Belgium*
Roland Schmitt, Hannover, Germany

Mini Lecture

Assisted PD: strategies and outcomes
Anna Giuliani, Vicenza, Italy

Free communications

Su587
CARDIAC GEOMETRY, FUNCTION, AND REMODELING PATTENRS AND LUNG WATER CONTENT IN PATIENTS UNDER MAINTENANCE HEMODIALYSIS AND PERITONEAL DIALYSIS TREATMENT.
Maria Eleni Alexandrou, Thessaloniki, Greece

Scientific Programme

Su1902
PD INDUCED ARTERIOLAR AND PERITONEAL PATHOMECHANISMS ARE PARTIALLY REVERSED AFTER KIDNEY TRANSPLANTATION
Conghui Zhang, Heidelberg, Germany

Su2104 LITHIUM PRESERVES PERITONEAL MEMBRANE INTEGRITY BY REDUCING MESOTHELIAL CELL AB-CRYSTALLIN
Rebecca Herzog, Vienna, Austria

Su2209
TOWARDS RAPID BEDSIDE TESTING FOR THE DIAGNOSIS OF PD-ASSOCIATED COMPLICATIONS
Klaus Kratochwill, Vienna, Austria

STOP DIABETES

Free Communication Session 22 — Hall New York - 17:00-18:30 (CEST)

Chairs: *Sebastjan Bevc, Maribor, Slovenia*
Khaled Khazim, Nahariya, Israel

Free communications

Su504
MIR-155/SOCS1 REGULATORY LOOP INFLUENCES DIABETIC KIDNEY DISEASE BY JAK/STAT PATHWAY MODULATION
Ignacio Prieto, Madrid, Spain

Su648
LIPOTOXICITY MEDIATED BY GPR43 ACTIVATION CONTRIBUTES TO PODOCYTE INJURY IN DIABETIC NEPHROPATHY THROUGH MODULATING ERK/EGR1 PATHWAY
Jian Lu, Nanjing, China

Su1157
GLOMERULI PROTEOME ANALYSIS REVEALS EARLY DIFFERENCES BETWEEN PRE-EXISTING AND DE-NOVO TYPE 2 DIABETES IN HUMAN RENAL ALLOGRAFTS
Jessica Furriol, Bergen, Norway

Su2082
DUAL BLOCKADE OF ENDOTHELIN A RECEPTOR (ETA) AND SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) TO PREVENT DIABETIC KIDNEY DISEASE PROGRESSION ON A TYPE 2 MURINE MODEL.
Ander Vergara Arana, Barcelona, Spain

Su2130
SERUM INTERLEUKIN-6 LEVELS PREDICT RENAL DISEASE PROGRESSION IN DIABETIC KIDNEY DISEASE
Beatriz Sanchez Alamo, Alcorcón, Spain

AVOIDING A CRASH LANDING OF NEPHROLOGY BY CREATING AWARENESS

Symposium 0.5 — Virtual Hall 1 - 17:00-18:30 (CEST)

Chairs: *Raymond Vanholder, Ghent, Belgium*
Valerie Luyckx, Erlenbach, Switzerland

1. The burden of kidney disease: the unbearable lightness of neglect
Raymond Vanholder, Ghent, Belgium

2. The burden of COVID-19 on the population with kidney disease
Marlies Noordzij, Groningen, Netherlands

3. US Actions to Create Awareness on Kidney Disease and International Cooperation to Address Kidney Failure
Murray Sheldon, Washington, DC, United States of America

A LOOK IN THE CRYSTAL BALL: ENVIRONMENT & EDUCATION

Free Communication Session 34 + Mini Lectures — Virtual Hall 2 - 17:00-18:30 (CEST)

Chairs: *Cécile Legallais, Compiègne, France*
Francesco Paolo Schena, Bari, Italy

Mini Lecture

Achieving sustainable development goals in nephrology care, research and education
Peter J. Blankestijn, Utrecht, Netherlands

Mini Lecture

Nephrology education: Looking to the Future
David Lappin, Galway, Ireland

Free communications

Su1027
WATER SAVING COMPARISON AT DIFFERENT DIALYSATE FLOWS IN EXPANDED HEMODIALYSIS
Alejandra Molano-Triviño, Vicenza, Italy

Su1217
A STEP TOWARD GREEN NEPHROLOGY: APPLYING THE PASSIVE HOUSE CONCEPT TO THE CONSTRUCTION OF DIALYSIS FACILITIES
Christophe Mariat, Saint-Etienne, France

era edta
LEADING EUROPEAN NEPHROLOGY



NDT-Educational gets a new look! Discover our new online educational portal

NEP era edta
LEADING EUROPEAN NEPHROLOGY
NEPHROLOGY EDUCATION PORTAL

NEW! Our bi-monthly newsletter will soon offer exclusive Membership benefits, like:
ON-LINE COURSES

www.era-edta.org/en/nep/

Day at a glance
Monday, 07 June 2021

AKI: THE GOOD, THE BAD & THE UGLY page 40
MEMBRANOUS NEPHROPATHY: INSIGHTS FROM RECENT CLINICAL TRIALS page 40

COVID-19 IN HAEMODIALYSIS PATIENTS page 41
CKD AND METABOLIC DISORDERS: THE COMMON COGNITIVE OUTCOME page 41
2021 PEARLS OF NDT AND CKJ page 41

ACID-BASE BALANCE IN HEALTH AND KIDNEY DISEASE page 42
NETWORKS AND REGISTRIES IN RARE KIDNEY DISEASES page 42
CLIMATE CHANGE AND HEALTH: THE OPINION OF THE YOUNGER GENERATION page 42

DIALYSIS: NUTRITION & OUTCOMES page 43

ERA-EDTA GENERAL ASSEMBLY page 44

MODERATED MINI-ORALS 3 page 45

PLENARY LECTURE 2 page 46
BONES & OUTCOMES IN CKD page 46

RANDOMIZED TRIALS - SLOWING THE PROGRESSION OF CKD page 47

TRANSPLANT CLINICAL MEDICINE page 48
EXTRACELLULAR VESICLES AND KIDNEY DISEASES: FROM BIO-MARKERS TO THERAPEUTIC BIO-PRODUCTS page 48
PD VS HD: SIMILARITIES AND DIFFERENCES, AN ENDLESS DEBATE page 48

KIDNEY STONES page 49
PREVENTION OF AKI page 49

BEAT AUTOIMMUNITY page 50
ANCA VASCULITIS PROGNOSTIC AND TREATMENT page 50
PLANTS, COFFEE & MORE page 50

CYSTS AND CANCER page 51

KDIGO BP IN CKD CONTROVERSIAL GUIDELINE 2021 page 52
COMPLICATED LUPUS NEPHRITIS page 52
UP-TO-DATE ON ALPORT SYNDROME page 52

INNOVATIONS IN HAEMODIALYSIS page 53
MICROBIOME IN CKD page 53
KIDS & KIDNEY page 53

TREAT DIABETES page 54

THE NEPHROTOXICITY OF COMMONLY USED MEDICATIONS: WHAT IS THE EVIDENCE AND WHAT ARE THE ALTERNATIVES page 55
CELLS & IMMUNITY page 55

MODERATED MINI-ORALS 4 page 56

BASICS & CLINICS IN GLOMERULONEPHRITIS page 57

VOLUME CONTROL IN PERITONEAL DIALYSIS page 58
NEW CONCEPTS IN CARDIOVASCULAR DISEASE IN CKD PATIENTS page 58
NEW ASPECTS IN AKI PREVENTION AND TREATMENT page 58

NEW MECHANISMS OF GRAFT DAMAGE IN KIDNEY TRANSPLANTATION page 59
UPDATES ON ADPKD page 59
PATHOLOGY MEETS CLINICS page 59

DIALYSIS PATTERNS: WHAT'S NEW? page 60
VOLUME AND BLOOD PRESSURE CONTROL IN DIALYSIS page 60

TRANSPLANTATION: RISKS & COMPLICATIONS page 61

Scientific Programme

AKI: THE GOOD, THE BAD & THE UGLY

Free Communication Session 13 + Mini Lectures — Virtual Hall 1 - 08:00-09:30 (CEST)

Chairs: *Nicholas Selby, Nottingham, United Kingdom*
Andreas Kribben, Essen, Germany

Mini Lecture

AKI biomarkers as prognostic marker for development of CKD
Danilo Fliser, Homburg, Germany

Free communications

Mo1202
COMPARISON OF THE CHARACTERISTICS AND MORTALITY OF ACUTE KIDNEY INJURY IN PATIENTS WITH COVID-19 AND OTHER RESPIRATORY INFECTIONS: A PROSPECTIVE COHORT STUDY.
Matthias Diebold, Basel, Switzerland

Mo1729
IS AKI IN COVID-19 PATIENTS ASSOCIATED WITH INCREASED LENGTH OF STAY AND MORTALITY?
Jennifer Ng, London, United Kingdom

Mo1826
INCIDENCE OF NOSOCOMIAL ACUTE KIDNEY INJURY (AKI) IN A COHORT OF COMMUNITY-DWELLING OLDER ADULTS OVER 8 YEARS OF OBSERVATION
Natalie Ebert, Berlin, Germany

Mo1845
URINARY LEVELS OF SARS-COV-2 NUCLEOCAPSID PROTEIN PREDICTS AKI AND FATAL OUTCOME IN COVID-19
Björn Tampe, Göttingen, Germany

MEMBRANOUS NEPHROPATHY: INSIGHTS FROM RECENT CLINICAL TRIALS

Symposium 3.3 — Hall A3-7 (Plenary) - 08:00-09:30 (CEST)

Chairs: *Andreas Kronbichler, Innsbruck, Austria*
Hans Joachim Anders, Munich, Germany

1. The role of anti-PLA2R monitoring
Pierre Ronco, Paris, France

2. Rituximab as first line therapy
Giuseppe Remuzzi, Bergamo, Italy

3. Back to basics. Cyclophosphamide/steroids
Manuel Praga, Madrid, Spain

COVID-19 IN HAEMODIALYSIS PATIENTS

Symposium 5.2 — Hall A8 - 08:00-09:30 (CEST)

Chairs: *Marc H. Hemmelder, Utrecht, Netherlands*
Rita Suri, Montreal, Canada

1. Prevention strategies for minimizing SARS-CoV-2 infection in dialysis facilities
Mario Cozzolino, Milan, Italy

2. Infection control in dialysis units
Patricia De Sequera Ortiz, Madrid, Spain

3. Outcomes in dialysis patients infected with SARS-CoV-2
Marian Goicoechea, Madrid, Spain

CKD AND METABOLIC DISORDERS: THE COMMON COGNITIVE OUTCOME

Symposium 4.4 — Hall Budapest - 08:00-09:30 (CEST)

Chairs: *Gioacchino Tedeschi, Naples, Italy*
Dorothea Nitsch, London, United Kingdom

1. Cognitive impairment in CKD
Davide Viggiano, Naples, Italy

2. Clinical testing for cognitive function in CKD patients
Marion Pepin, Paris, France

3. Cognitive impairment and albuminuria/hypertension
Pilar Delgado, Barcelona, Spain

2021 PEARLS OF NDT AND CKJ

Symposium 0.4 — Hall Helsinki - 08:00-09:30 (CEST)

Chairs: *Denis Fouque, Pierre-Bénite, France*
Alberto Ortiz, Madrid, Spain

1. NDT Editor selects 2 Speakers from associate Editors
Kate Stevens, Glasgow, United Kingdom
Martin De Borst, Groningen, Netherlands

2. CKJ Editor selects 2 Speakers from the Editorial Board
Pierre Delanaye, Liege, Belgium
Ana Carina Ferreira, Lisbon, Portugal

Scientific Programme

ACID-BASE BALANCE IN HEALTH AND KIDNEY DISEASE

Symposium 1.1 — Hall London - 08:00-09:30 (CEST)

Chairs: *Stephen Walsh, London, United Kingdom*
Donald Wesson, Dallas, TX, United States of America

1. The renal response to acid(osis)
Francesco Trepiccione, Naples, Italy

2. Acidosis in patients with kidney transplant: origin and impact on outcome
Nilufar Mohebbi, Zurich, Switzerland

3. Alkali treatment and amelioration of kidney disease – uncovering underlying mechanisms
Pedro H Imenez Silva, Zurich, Switzerland

NETWORKS AND REGISTRIES IN RARE KIDNEY DISEASES

Symposium 2.4 — Hall New York - 08:00-09:30 (CEST)

Chairs: *Elena Levtchenko, Leuven, Belgium*
Aude Servais, Paris, France

1. ERKNet and its future perspectives
Franz Schaefer, Heidelberg, Germany

2. Registries in paediatric nephrology
Maria Gema Ariceta Iraola, Barcelona, Spain

3. PKD registries
Albert Ong, Sheffield, United Kingdom

CLIMATE CHANGE AND HEALTH: THE OPINION OF THE YOUNGER GENERATION

Symposium 0.7 — Virtual Hall 1 - 08:00-09:30 (CEST)

Chairs: *Giovambattista Capasso, Naples, Italy*
Christoph Wanner, Würzburg, Germany

1. Global perspective on the climate crisis as a crisis of health
Martin Herrmann, Munich, Germany

2. Repercussions of heatwaves for kidney patients
Christian Witt, Berlin, Germany

3. Perspectives for the coming medical generation regarding the climate crisis
Sylvia Hartmann, Berlin, Germany

Scientific Programme

Round table: *Lisa Pörtner, Bremen, Germany*
Norbert Kamin, Hamburg, Germany
Marlene Thöne, Tübingen, Germany
Louise Hegge, Munich, Germany
Sophie Gepp, Berlin, Germany
Sophia Galle, Würzburg, Germany

DIALYSIS: NUTRITION & OUTCOMES

Free Communication Session 29 + Mini Lectures — Virtual Hall 2 - 08:00-09:30 (CEST)

Chairs: *Giuliano Brunori, Trento, Italy*
Peter Stenvinkel, Stockholm, Sweden

Mini Lecture

Nutritional impact of HDF, a randomized trial
Pablo Molina, Valencia, Spain

Free communications

Mo296
WEIGHT CHANGE AS A PREDICTOR OF MORTALITY IN CHRONIC HEMODIALYSIS PATIENTS
Takuhiro Moromizato, Osaka, Japan

Mo1063
HIGHER VARIABILITY OF SERUM PHOSPHATE IS ASSOCIATED WITH INCREASED MORTALITY RISK ONLY WHEN ASSOCIATED WITH HYPOALBUMINEMIA
Karlien ter Meulen, Eindhoven, Netherlands

Mo1774
DIALYSIS WITHDRAWAL IN THE NETHERLANDS BETWEEN 2000-2020: TIME TRENDS AND CENTRE VARIATION
Mathijs van Oevelen, Leiden, Netherlands

Mo1862
TIME TRENDS IN PROBABILITY OF STARTING HOME DIALYSIS OVER A 20 YEAR PERIOD: A DUTCH REGISTRY STUDY
Anna Bonenkamp, Amsterdam, Netherlands

General Assembly

ERA-EDTA GENERAL ASSEMBLY

Hall A3-7 (Plenary) - 09:30-10:45 (CEST)

All ERA-EDTA active members are invited to participate in the ERA-EDTA General Assembly. Members (and their status of FULL or ASSOCIATE) will be automatically recognized by the system. Full members will be able to vote (Associate members - cannot vote but they can ask questions).

The General Assembly will be held virtually.

Members will be able to attend even if they are NOT registered to the Congress.

Part I - 09:30-09:40 (CEST)

1. Opening
   a. Welcome, *Christoph Wanner*
   b. Minutes of the 57th General Assembly, Virtual, *Ivan Rychlik*
   c. Matters arising from the minutes, *Ivan Rychlik*

Part II - 09:40-10:30 (CEST)

2. Report from the President, *Christoph Wanner*
3. Report from the Secretary-Treasurer, *Ivan Rychlik*
   a. Ratification of the 2020 Accounts
   b. Constitution changes approval, *Ivan Rychlik, Christoph Wanner*
4. Report from Renal Science Chair (Chair of the Administrative Offices), *Danilo Fliser*
5. Report from the Editor-in-Chief of NDT, *Denis Fouque*
6. Report from the Clinical Nephrology Governance Chair (Chair of the Registry), *Ziad Massy*

Part III - 10:30-10:45 (CEST)

7. Election of Ordinary Council Members (three vacancies), *Ivan Rychlik*
8. CKJ Editor-in-Chief Election Confirmation, *Ivan Rychlik*
9. Venue and date of future ERA-EDTA Congresses, *Ivan Rychlik*
10. Date and venue of the next General Assembly, *Ivan Rychlik*
11. Any other business, *Ivan Rychlik*
    a. FERA awards
12. Closure, *Christoph Wanner*



Scientific Programme

MODERATED MINI-ORALS 3

Moderated Mini-Orals Hall - 09:30-10:45(CEST)

Chairs: *Annette Bruchfeld, Stockholm, Sweden*
Andreas Kronbichler, Innsbruck, Austria

MO019
MATERNAL UNDERNUTRITION AMELIORATES CYST GROWTH IN ADPKD MODEL MICE
Junpei Yoshikawa, Sapporo, Japan

MO347
CENTER VARIATION IN LENGTH OF STAY FOR PATIENTS WITH HOSPITAL-ACQUIRED ACUTE KIDNEY INJURY IN ENGLAND
Javeria Peracha, Birmingham, United Kingdom

MO538
THE SHORT-TERM IMPACT OF HIGH DOSE INTRAVENOUS IRON USE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND IRON DEFICIENCY WITHOUT ANAEMIA - A POST-HOC ANALYSIS OF A MULTICENTRE RANDOMIZED CONTROLLED TRIAL
Xenophon Kassianides, Kingston Upon Hull, United Kingdom

MO563
HIGH DIALYSATE MAGNESIUM AND CORONARY ARTERY CALCIFICATION IN MAINTENANCE HEMODIALYSIS PATIENTS
Praopilad Srisuwarn, Bangkok, Thailand

MO633
GLYCAEMIC MARKERS IN PATIENTS WITH TYPE 2 DIABETES UNDERGOING HAEMODIALYSIS EVALUATED BY LONG-TERM CONTINUOUS GLUCOSE MONITORING
Tobias Bomholt, Copenhagen, Denmark

MO656
CORRELATION BETWEEN CHANGES IN THE BODY FLUID VOLUME CALCULATED BY THE URIC ACID KINETIC MODEL AND CHANGES IN THE BODY WEIGHT
Shigeru Nakai, Toyoake City, Japan

MO680
INTERNATIONAL COMPARISONS OF ICODEXTRIN PRESCRIPTION PRACTICE AND ITS ASSOCIATION WITH FLUID REMOVAL, BLOOD PRESSURE, PATIENT AND TECHNIQUE SURVIVAL
Simon Davies, Stoke-on-Trent, United Kingdom

MO792
CONTEMPORARY MINERAL AND BONE DISORDER MARKERS AND TREATMENT AMONG HEMODIALYSIS PATIENTS IN THE EUROPEAN DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)
Brian Bieber, Ann Arbor, MI, United States of America

MO809
DOES LISTENING TO LIVE MUSIC DURING HEMODIALYSIS SESIONS AFFECT THE QUALITY OF LIFE?
Alicia Garcia-Testal, Manises, Valencia, Spain

MO810
INTERLEUKIN-6 (-174G/C) POLYMORPHISM, RS1800795, IN ESRD PATIENTS' OUTCOME
Elsa Bronze-da-Rocha, Porto, Portugal

Scientific Programme

MO1005
ADPEDKD: A GLOBAL ONLINE PLATFORM TO EXPLORE THE CHILDHOOD PHENOTYPE OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Angélique Dachy, Oupeye, Belgium

MO1007
RELATIONSHIP BETWEEN DIALYSIS ADEQUACY, ULTRAFILTRATION RATE AND SURVIVAL IN YOUNG HEMODIALYSIS (HD) PATIENTS HAVING INITIATED CHRONIC HD IN CHILDHOD
Verena Gotta, Basel, Switzerland

MO1029
RENAL STONE DISEASE IN 193 PONTIFFS: FROM VIGILUS TO PIUS VIII (537-1830)
Carmela Bisaccia, Naples, Italy

MO1045
DEVELOPMENT OF A HOME CARE SUPPORT SYSTEM FOR PERITONEAL DIALYSIS PATIENTS I - USING DIGITAL WATERMARKING AND STEGANOGRAPHY
Tokuo Umeda, Machida, Japan

PLENARY LECTURE 2

Hall A3-7 (Plenary) - 10:45-11:30 (CEST)

Chairs: *Roser Torra, Barcelona, Spain*
Giovambattista Capasso, Naples, Italy

A novel biological mechanism underlying renal cystogenesis and tumorigenesis
Andrea Ballabio, Naples, Italy

BONES & OUTCOMES IN CKD

Free Communication Session 20 — Hall A1 - 11:45-13:15 (CEST)

Chairs: *Markus Ketteler, Stuttgart, Germany*
Alessandra Perna, Naples, Italy

Free communications

Mo82
REAL-WORLD EFFECTIVENESS OF ETELCALCETIDE VS. CINACALCET IN US HEMODIALYSIS PATIENTS: A FACILITY CALCIMIMETIC PREFERENCE APPROACH
Angelo Karaboyas, Ann Arbor, MI, United States of America

Mo311
DIAGNOSTIC ACCURACY OF BONE TURNOVER MARKERS IN RENAL OSTEODYSTROPHY
Hanne Skou Jørgensen, Aarhus, Denmark

Mo643
HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY
Pedro Barrera Baena, Oviedo, Spain

Scientific Programme

Mo1173
VARIABILITY IN SERUM PHOSPHATE ASSESSED BY DIRECTIONAL CHANGE IS ASSOCIATED WITH INCREASED MORTALITY
Xiaoling (Janice) Ye, York, PA, United States of America

Mo1572
LONG-TERM SAFETY OF TENAPANOR FOR THE CONTROL OF SERUM PHOSPHORUS IN PATIENTS WITH CKD ON DIALYSIS
David Rosenbaum, Waltham, MA, United States of America

RANDOMIZED TRIALS - SLOWING THE PROGRESSION OF CKD

Symposium 4.8 Hall A3-7 (Plenary) 11:45-13:15 (CEST)

Chairs: *Bo Feldt-Rasmussen, Copenhagen, Denmark*
Danilo Fliser, Homburg, Germany

DAPA-CKD
1. The DAPA-CKD trial. Primary results and insights from a kidney perspective, including: • Outcomes by CKD aetiology including IgA nephropathy and FSGS • Outcomes in Stage 4 CKD • In-depth data on mortality
Hiddo Lambers Heerspink, Groningen, Netherlands

2. DAPA-CKD - thinking beyond kidney disease. Glycaemic and cardiovascular outcomes, including: • Outcomes by diabetes status • Outcomes by baseline cardiovascular disease
Peter Rossing, Gentofte, Denmark

3. Clinical insight - How should we use SGLT2 inhibitors in nephrology?
David Wheeler, London, United Kingdom

Q&A

FIDELIO-DKD
1.Introduction
Luis Ruilope, Madrid, Spain

2. FIDELIO-DKD - Renal efficacy & safety
Rajiv Agarwal, Indianapolis, IN, United States of America

3. FIDELIO-DKD - CV outcomes including atrial fibrillation
Gerasimos Filippatos, Athens, Greece

Q&A

4. Summary
Luis Ruilope, Madrid, Spain

Discussant

3. The Big Three: how RASi, SGLT2i & MRA will change the treatment landscape for kidney patients
George Bakris, Chicago, IL, United States of America

Scientific Programme

TRANSPLANT CLINICAL MEDICINE

Symposium 7.3 — Hall A8 - 11:45-13:15 (CEST)

Chairs: *Julio Pascual, Barcelona, Spain*
Umberto Maggiore, Parma, Italy

1. Deceased Donor-initiated Chains: a way to avoid long waiting list
Lucrezia Furian, Padua, Italy

2. Organ preservation and reconditioning: the dream comes true
Henri Leuvenink, Groningen, Netherlands

3. Graft loss in non adherent patients: ethical challenges
Jadranka Buturovic, Ljubljana, Slovenia

EXTRACELLULAR VESICLES AND KIDNEY DISEASES: FROM BIO-MARKERS TO THERAPEUTIC BIO-PRODUCTS

Symposium 2.2 — Hall Budapest - 11:45-13:15 (CEST)

Chairs: *Benedetta Bussolati, Turin, Italy*
Gabriella Pocsfalvi, Naples, Italy

1. Extracellular vesicles from urine and beyond
Uta Erdbruegger, Charlottesville, VA, United States of America

2. EVs as markers/mediators of vascular ageing
Vincenzo Cantaluppi, Novara, Italy

3. Exosomes and microvesicles as biomarkers in renal physiology and diseases
Diana Karpman, Lund, Sweden

PD VS HD: SIMILARITIES AND DIFFERENCES, AN ENDLESS DEBATE

Symposium 6.3 — Hall Dublin - 11:45-13:15 (CEST)

Chairs: *Liliana Garneata, Bucharest, Romania*
Raymond T. Krediet, Amsterdam, Netherlands

1. Sleep apnea and sleep quality in dialysis patients; an emerging cardiovascular risk factor?
Francesca Mallamaci, Reggio Calabria, Italy

2. Technical methods for volume evaluation in ESKD; are there differences between haemodialysis and peritoneal dialysis?
Robert Ekart, Maribor, Slovenia

3. Regulation of central haemodynamics and blood pressure in haemodialysis and peritoneal dialysis; is “more stable” also better?
Olga Balafa, Ioannina, Greece

KIDNEY STONES

Symposium 3.7 — Hall Helsinki - 11:45-13:15 (CEST)

Chairs: *Giovanni Gambaro, Verona, Italy*
Philippe Jaeger, Lully, Switzerland

1. From crystals to CKD
Felix Knauf, Berlin, Germany

2. Urate transporters, gout and urate nephropathy
Olivier Bonny, Lausanne, Switzerland

3. ABC of Randall's plaques and stones: from rare diseases to calcium nephrolithiasis
Emmanuel Letavernier, Paris, France

PREVENTION OF AKI

Free Communication Session 14 + Mini Lectures — Hall London - 11:45-13:15 (CEST)

Chairs: *Laura Cosmai, Pavia, Italy*
Marlies Ostermann, London, United Kingdom

Mini Lecture

AKI and cancer
Ben Sprangers, Leuven, Belgium

Free communications

Mo936
A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS
David Jayne, Cambridge, United Kingdom

Mo641
ACID-BASE BALANCE DURING IN-SERIES EXTRACORPOREAL CARBON DIOXIDE REMOVAL AND CONTINUOUS VENOVENOUS HEMOFILTRATION: PREDICTIONS FROM A MATHEMATICAL MODEL
John (Ken) Leypoldt, Warsaw, Poland

Mo665
PREDICTIVE VALUE OF PLASMA NGAL:HEPCIDIN-25 FOR MAJOR ADVERSE KIDNEY EVENTS AFTER CARDIAC SURGERY WITH CARDIOPULMONARY BYPASS: A PILOT STUDY
Michael Haase, Potsdam, Germany

Mo2174
THE PREDICTIVE ABILITY OF URINARY BIOMARKERS FOR PROGRESSION OF ACUTE KIDNEY INJURY IN CRITICAL ILLNESS.
Stephen Duff, Dublin, Ireland

Scientific Programme

BEAT AUTOIMMUNITY

Free Communication Session 10 — Hall New York - 11:45-13:15 (CEST)

Chairs: *Mårten Segelmark, Lund, Sweden*
Kultigin Turkmen, Konya, Turkey

Free communications

★ Mo76
THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE
David Jayne, Cambridge, United Kingdom

Mo420
VOCLOSPORIN INCREASES RENAL RESPONSE AT COMMONLY USED UPCR THRESHOLDS IN PATIENTS WITH LUPUS NEPHRITIS
Paola Mina-Osorio, Victoria, Canada

Mo562
IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY
Edwin Kwan Soon Wong, Newcastle upon Tyne, United Kingdom

★ Mo911
SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS: A 6-MONTH OPEN-LABEL EXTENSION
Brad Rovin, Columbus, OH, United States of America

Mo1324
LONG-TERM FOLLOW-UP OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS INCLUDED IN EUROPEAN VASCULITIS SOCIETY RANDOMISED CLINICAL TRIALS SINCE 1995: A SURVIVAL ANALYSIS
Beatriz Sanchez Alamo, Lund, Sweden

ANCA VASCULITIS PROGNOSTIC AND TREATMENT

Symposium 3.6 — Virtual Hall 1 - 11:45-13:15 (CEST)

Chairs: *Annette Bruchfeld, Stockholm, Sweden*
Dario Roccatello, Turin, Italy

1. ANCA vasculitis and treatment. Where are we now?
David Jayne, Cambridge, United Kingdom

2. Urinary CD163 in antineutrophil cytoplasm antibody-associated glomerulonephritis
Gema Fernandez-Juarez, Madrid, Spain

3. Renal risk score for ANCA vasculitis
Juan Manuel Mejia Vilet, Mexico City, Mexico

PLANTS, COFFEE & MORE

Free Communication Session 21 + Mini Lectures — Virtual Hall 2 - 11:45-13:15 (CEST)

Chairs: *Carla Avesani, Stockholm, Sweden*
Juan Jesus Carrero, Stockholm, Sweden

Mini Lecture

Coffee and mortality in CKD
Miguel Bigotte Vieira, Lisbon, Portugal

Mini Lecture

Plant based diets in CKD: benefits and risks
Juan Jesus Carrero, Stockholm, Sweden

Free communications

Mo503
ULTRA-PROCESSED FOOD CONSUMPTION AND RISK OF INCIDENT CHRONIC KIDNEY DISEASE: THE LIFELINES COHORT
Qingqing Cai, Groningen, Netherlands

Mo826
PROBIOTIC L.CASEI ZHANG SLOWS THE PROGRESSION OF ACUTE AND CHRONIC KIDNEY DISEASE
Rui Zeng, Wuhan, China

Mo1038
DIET QUALITY, PROTEIN-BOUND URAEMIC TOXINS AND GASTROINTESTINAL MICROBIOME IN CHRONIC KIDNEY DISEASE
Catherine McFarlane, Birtinya, Australia

CYSTS AND CANCER

Free Communication Session 03 + Mini Lectures — Hall A1 - 15:00-16:30 (CEST)

Chairs: *Jolanta Malyszko, Warsaw, Poland*
Roberta Ranieri, Casavatore, Italy

Mini Lecture

Bardet-Biedle Syndrome: from clinic to omics
Miriam Zacchia, Naples, Italy

Mini Lecture

Leveraging animal models for onconephrology research
Anna Capasso, Austin, TX, United States of America

Free communications

Mo407
CIRCULATING BIOMARKERS OF COLLAGEN TURNOVER ARE ASSOCIATED WITH DISEASE SEVERITY IN PATIENTS WITH ADPKD
Nadja Sparding, Copenhagen, Denmark

Mo1179
INTERDEPENDENT REGULATION OF POLYCYSTIN EXPRESSION INFLUENCES STARVATION-INDUCED AUTOPHAGY AND CELL DEATH
Jean-Paul Decuypere, Leuven, Belgium

Mo1220
4-WEEK ANTIBIOTIC THERAPY PREVENTS RECURRENT RENAL CYST INFECTIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Julien Dang, Paris, France

KDIGO BP IN CKD CONTROVERSIAL GUIDELINE 2021

Symposium 8.5 — Hall A3-7 (Plenary) - 15:00-16:30 (CEST)

Chairs: *Johannes F.E. Mann, Munich, Germany*
Carmine Zoccali, Reggio Calabria, Italy

1. Lowering systolic BP in CKD to <120 mm Hg is reasonable
Con *Indranil Dasgupta, Birmingham, United Kingdom*
Pro *Alfred C Cheung, Salt Lake City, UT, United States of America*

2. BP measurement in the office: Standardized measurement is vital and feasible
Con *Bernhard Kraemer, Mannheim, Germany*
Pro *Rajiv Agarwal, Indianapolis, IN, United States of America*

COMPLICATED LUPUS NEPHRITIS

Symposium 3.5 — Hall A8 - 15:00-16:30 (CEST)

Chairs: *Vladimir Tesar, Prague, Czech Republic*
Marten Segelmark, Lund, Sweden

1. Management of refractory lupus nephritis
Hans-Joachim Anders, Munich, Germany

2. Urinary exosomal miRNA expression profile in lupus nephritis
Benedetta Bussolati, Turin, Italy

3. Improved clarity of definitions and classification of glomerular lesions in lupus nephritis
Agnes Fogo, Nashville, TN, United States of America ISN

UP-TO-DATE ON ALPORT SYNDROME

Symposium 3.8 — Hall Budapest - 15:00-16:30 (CEST)

Chairs: *Oliver Gross, Goettingen, Germany*
Jeffrey Miner, St. Louis, MO, United States of America

1. Linking basement membrane biology to glomerular disease
Rachel Lennon, Manchester, United Kingdom

2. Ongoing clinical trials
Michelle Rheault, Minneapolis, MN, United States of America

3. New pathogenetic mechanisms and therapeutic implications
Alessia Fornoni, Miami, FL, United States of America

INNOVATIONS IN HAEMODIALYSIS

Symposium 5.3 — Hall Dublin - 15:00-16:30 (CEST)

Chairs: *Ivan Rychlik, Prague, Czech Republic*
Frank van der Sande, Maastricht, Netherlands

1. The long journey towards a portable/wearable dialysis. What can we expect in the future?
Karin Gerritsen, Utrecht, Netherlands

2. New haemodialysis therapies: HDx therapy – new membranes and others. Do they mean any real improvement?
Marie Evans, Stockholm, Sweden

3. How to reduce organ ischemia during haemodialysis: can modern technologies help us?
Chris McIntyre, Toronto, Canada

MICROBIOME IN CKD

Symposium 4.2 — Hall Helsinki - 15:00-16:30 (CEST)

Chairs: *Pieter Evenepoel, Leuven, Belgium*
Loreto Gesualdo, Altamura, Italy

1. Personalized targeting of the microbiome
Laetitia Koppe, Lyon, France

2. Microbiota in CKD: how promising are gut-targeted approaches?
Carmela Cosola, Bari, Italy

3. Exploring functional interactions between microbiota and host
Alessandra Perna, Naples, Italy

KIDS & KIDNEY

Free Communication Session 33 + Mini Lectures — Hall London - 15:00-16:30 (CEST)

Chairs: *Rezan Topaloglu, Ankara, Turkey*
Elena Levtchenko, Leuven, Belgium

Mini Lectures

Diagnosis and management of nephrotic syndrome in children: clinical practice guidelines from IPNA, ESPN and ERKNet
Dieter Haffner, Hannover, Germany

Free communications

★ Mo166
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3B TRIAL OF TOLVAPTAN IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): 1-YEAR DATA
Djalila Mekahli, Leuven, Belgium

Mo394
HEMODIAFILTRATION IS ASSOCIATED WITH REDUCED INFLAMMATION AND INCREASED BONE TURNOVER COMPARED TO CONVENTIONAL HEMODIALYSIS IN CHILDREN - THE HDF, HEART AND HEIGHT (3H) STUDY
Francesca De Zan, London, United Kingdom

Mo1050
SHORT COURSE DAILY LOW-DOSE PREDNISOLONE AT THE TIME OF UPPER RESPIRATORY TRACT INFECTION (URTI) IN NON-SELECTED CHILDREN WITH RELAPSING STEROID SENSITIVE NEPHROTIC SYNDROME DOES NOT PREVENT URTI-RELATED RELAPSE: THE PREDNOS 2 TRIAL.
Martin Christian, Nottingham, United Kingdom

Mo1293
OFATUMUMAB OR RITUXIMAB FOR CHILDREN WITH STEROID-DEPENDENT NEPHROTIC SYNDROME. A RANDOMIZED CONTROLLED TRIAL
Andrea Angeletti, Genoa, Italy

TREAT DIABETES

Free Communication Session 23 + Mini Lectures Hall New York - 15:00-16:30 (CEST)

Chairs: *Ivo Laranjinha, Lisbon, Portugal*
Beatriz Fernandez Fernandez, Madrid, Spain

Mini Lecture

Renal histology in patients with type 2 diabetes: the hidden role of vascular damage
Esteban Porrini, La Esperanza, Spain

Free communications

Mo720
EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D
Luis Ruilope, Madrid, Spain

Mo864
EFFECT OF GEMIGLIPTIN ON BIOMARKERS OF KIDNEY INJURY AND VASCULAR CALCIFICATION IN DIABETIC NEPHROPATHY: A RANDOMIZED CONTROLLED TRIAL
Thananda Trakarnvanich, Bangkok, Thailand

Mo1860
EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL
David C. Wheeler, London, United Kingdom

Mo1890
URINARY CCL5 MRNA, A POTENTIAL BIOMARKER FOR PROGRESSION OF TYPE 2 DIABETIC NEPHROPATHY
Songtao Feng, Nanjing, China

THE NEPHROTOXICITY OF COMMONLY USED MEDICATIONS: WHAT IS THE EVIDENCE AND WHAT ARE THE ALTERNATIVES

Symposium 3.9 — Virtual Hall 1 - 15:00-16:30 (CEST)

Chairs: *Catalina Martin Cleary, Madrid, Spain*
Goce Spasovski, Skopje, Republic of North Macedonia

1. Proton pump inhibitors
Laurie A Tomlinson, London, United Kingdom

2. Oral anticoagulants
Sergey Brodsky, Columbus, OH, United States of America

3. Paracetamol
Vanessa Perez-Gomez, Madrid, Spain

CELLS & IMMUNITY

Free Communication Session 02 + Mini Lectures — Hall A1 - 15:00-16:30 (CEST)

Chairs: *Dimitrios Goumenos, Patras, Greece*
Armin Kurtz, Regensburg, Germany

Mini Lecture

Salt and immunity
Bernardo Rodríguez-Iturbe, Maracaibo, Venezuela

Free communications

Mo736
DEPOSITION OF PLATELET-DERIVED MICRO-PARTICLES IN PODOCYTES CONTRIBUTES TO DIABETIC NEPHROPATHY.
Sijia Huang, Nanjing, China

Mo1301
CKD DERIVED MUSCLE CELLS RETAIN PHENOTYPIC CHARACTERISTICS OF UREIC SARCOPENIA: THE NEXT STEP IN CELLULAR MODELLING FOR THERAPEUTIC SCREENING
Luke Baker, Leicester, United Kingdom

Mo1687
PHOSPHATE FACILITATES PHOSPHATURIA BY PIT-2-MEDIATED ACTIVATION OF ERK1/2 SIGNALLING INTERNALIZING NAPI-2A FROM THE APICAL BRUSH BORDER MEMBRANE INDEPENDENT OF FGF23
Stefanie Walter, Hannover, Germany

Mo1692
PP2A PHOSPHATASE INHIBITION IS ANTI-FIBROTIC THROUGH SER77 PHOSPHORYLATION-MEDIATED ARNT/ARNT HOMODIMER FORMATION
Gunsmaa Nyamsuren, Goettingen, Germany

Scientific Programme

MODERATED MINI-ORALS 4

Moderated Mini-Orals Hall - 16:30-17:45(CEST)

Chairs: *Oshorenua Aiyegbusi, Glasgow, United Kingdom*
Alexander Rosenkranz, Graz, Austria

MO125
NON-AMYLOID TYPE OF MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: CLINICAL AND MORPHOLOGICAL SPECTRUM AND LONG-TERM RENAL OUTCOME
Maria Khrabrova, Saint-Petersburg, Russia

MO127
CLEARED PODOCYTES AND NORMAL KIDNEY FUNCTION IN CLASSICAL FABRY MALES 15 YEARS AFTER START OF ENZYME REPLACEMENT THERAPY AT YOUNG AGE
Camilla Tøndel, Bergen, Norway

MO128
RETINOL BINDING PROTEIN (RBP) - NEW BIOMARKER OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS
Karolina Woziwodzka, Krakow, Poland

MO244
CD47 BLOCKADE AMELIORATES AUTOIMMUNE VASCULITIS VIA THE EFFEROCYTOSIS OF NEUTROPHIL EXTRACELLULAR TRAPS
Satoka Shiratori-Aso, Sapporo, Japan

MO245
OUTCOME OF DIFFERENT INDUCTION REGIMENS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS ACCORDING TO THE HISTOPATHOLOGICAL CHARACTERISTICS: THE REASSESS STUDY
Martina Uzzo, Milan, Italy

MO250
URINARY DICKKOPF-3 (UDKK3): A NEW BIOMARKER FOR LONG-TERM CKD PROGRESSION AND MORTALITY?
Beatriz Sanchez Alamo, Madrid, Spain

MO251
HIGHLY SENSITIVE FLOW CYTOMETRIC DETECTION OF RESIDUAL B-CELLS AFTER RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS PATIENTS
Y.K.O. Teng, Leiderdorp, Netherlands

MO254
PREGNANCY OUTCOMES AND COMPLICATIONS IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS
Aleksei Zulkarnaev, Moscow, Russia

MO428
25-HYDROXYVITAMIN D AND TUBULAR DYSTROPHY IN PATIENTS WITH CKD STAGES 1-3
Olga Galkina, Saint Petersburg, Russia

MO439
NATURAL IMMUNISATION AGAINST ATHEROSCLEROSIS IN BEARS DURING HIBERNATION
Peter Stenvinkel, Stockholm, Sweden

Scientific Programme

MO440
KLOTHO AS A BIOMARKER OF SUBCLINICAL CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A PROOF-OF-CONCEPT STUDY.
Carla Ferri, Santa Cruz de Tenerife, Spain

MO441
CALPROTECTIN IS A NOVEL CONTRIBUTING FACTOR IN VASCULAR CALCIFICATION AND A PREDICTOR OF CARDIOVASCULAR OUTCOME IN CKD PATIENTS
Ana Amaya-Garrido, Toulouse, France

MO443
EFFECTS OF SHORT-TERM POTASSIUM CHLORIDE SUPPLEMENTATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Martin Gritter, Rotterdam, Netherlands

MO482
URINE METABOLITE LEVELS OF CKD PATIENTS ARE ASSOCIATED WITH ADVERSE KIDNEY OUTCOMES AND MORTALITY
Inga Steinbrenner, Freiburg, Germany

MO876
ESTIMATING THE BUDGET IMPACT OF DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE FROM A UK PAYER PERSPECTIVE
Phil McEwan, Cardiff, United Kingdom

BASICS & CLINICS IN GLOMERULONEPHRITIS

Free Communication Session 09 + Mini Lectures — Hall A1 - 17:00-18:30 (CEST)

Chairs: *Nicole Endlich, Greifswald, Germany*
Maria Dolores Sanchez-Nino, Madrid, Spain

Mini Lecture

MicroRNA and kidney pathophysiology
Laurent Metzinger, Amiens, France

Mini Lecture

Mesenchymal Stem Cell Therapy for Glomerulonephritis
Shoichi Maruyama, Nagoya, Japan

Free communications

Mo114
CONTACTIN-1 IS A NOVEL ANTIGEN IN IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS AND IN CIDP- ASSOCIATED GLOMERULONEPHRITIS
Alan Salama, London, United Kingdom

Mo117
PODOCYTE AND GLOMERULAR ENDOTHELIAL CELL DERIVED MICRORNAS REGULATE PODOCYTE NEPHRONECTIN IN MEMBRANOUS GLOMERULONEPHRITIS
Janina Müller-Deile, Erlangen, Germany

Mo2152
LARGE SCALE VALIDATION OF THE NEW INTERNATIONAL PROGNOSTIC SCORE OF IGA NEPHROPATHY ON A FRENCH COHORT WITH PROLONGED FOLLOW-UP.
Grégoire Bon, Saint-Étienne, France

Scientific Programme

VOLUME CONTROL IN PERITONEAL DIALYSIS

Symposium 6.2 — Hall A3-7 (Plenary) - 17:00-18:30 (CEST)

Chairs: *Sandip Mitra, Manchester, United Kingdom*
Eric Goffin, Brussels, Belgium

1. Which biomarkers should we use?
Anabela Rodrigues, Porto, Portugal

2. Does bioimpedance have a role in volume control?
Wim Van Biesen, Ghent, Belgium

3. The anuric patient - is there a space for weekly hypertonic solutions?
Nicola Matthews, Toronto, Canada

NEW CONCEPTS IN CARDIOVASCULAR DISEASE IN CKD PATIENTS

Symposium 8.1 — Hall A8 - 17:00-18:30 (CEST)

Chairs: *Marianne Verhaar, Utrecht, Netherlands*
Jonathan Fox, Glasgow, United Kingdom

1. Treatment of atrial fibrillation in patients with CKD: a way between Scylla and Charybdis?
Charles Ferro, Birmingham, United Kingdom

2. Blood-pressure insensitive arterial stiffness: the major cardiovascular risk factor in ESRD?
Gerard London, Paris, France

3. The role of endothelial glycocalyx in health and disease
Mehmet Kanbay, Istanbul, Turkey

NEW ASPECTS IN AKI PREVENTION AND TREATMENT

Symposium 9.4 — Hall Budapest - 17:00-18:30 (CEST)

Chairs: *Andrzej Wiecek, Katowice, Poland*
Norbert Lameire, Ghent, Belgium

1. Cost-effective prevention strategies for AKI
Melanie Meersch, Münster, Germany

2. “Subclinical” AKI - does it matter?
Jill Vanmassenhove, Ghent, Belgium

3. New treatment options for AKI - does anything work?
John A. Kellum, Pittsburgh, PA, United States of America

NEW MECHANISMS OF GRAFT DAMAGE IN KIDNEY TRANSPLANTATION

Symposium 7.4 — Hall Dublin - 17:00-18:30 (CEST)

Chairs: *Luuk Hilbrands, Nijmegen, Netherlands*
Marta Crespo, Barcelona, Spain

1. Preserving the donor: new therapeutic approaches
Cees van Kooten, Leiden, Netherland

2. Machine perfusion: optimizing the protocol for better preservation
Rutger J. Ploeg, Oxford, United Kingdom

3. Inflammaging and complement system: from acute kidney injury to chronic graft damage
Giuseppe Castellano, Foggia, Italy

UPDATES ON ADPKD

Symposium 2.5 — Hall Helsinki - 17:00-18:30 (CEST)

Chairs: *Kai Uwe Eckardt, Berlin, Germany*
Emilie Cornec-Le Gall, Brest, France

1. Metabolic reprogramming in ADPKD
Alessandra Boletta, Milan, Italy

2. The role of chloride secretion in ADPKD
Björn Buchholz, Erlangen, Germany

3. Imaging and genotyping to predict the outcome of ADPKD
Vicente Torres, Rochester, MN, United States of America

PATHOLOGY MEETS CLINICS

Free Communication Session 05 + Mini Lectures — Hall London - 17:00-18:30 (CEST)

Chairs: *Pablo Cannata-Ortiz, Madrid, Spain*
Jan Ulrich Becker, Cologne, Germany

Mini Lecture

The renal lymphatic system
Dontscho Kerjaschki, Vienna, Austria

Mini Lecture

Update on diagnosis and therapy for non-AL amyloidosis
Tamer Rezk, London, United Kingdom

Free communications

Mo573
LACK OF PLASMINOGEN RELATES TO A HYPERCOAGULABLE STATE IN MICE WITH

EXPERIMENTAL NEPHROTIC SYNDROME
Mengyun Xiao, Tübingen, Germany

Mo1132
SPARSENTAN IMPROVES GLOMERULAR BLOOD FLOW AND AUGMENTS PROTECTIVE TISSUE REMODELING IN MOUSE MODELS OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Georgina Gyarmati, Los Angeles, CA, United States of America

Mo2392
DEEP-LEARNING ENABLED QUANTIFICATION OF SINGLE-CELL SINGLE-MRNA TRANSCRIPTS AND CORRELATIVE SUPER-RESOLVED PODOCYTE FOOT PROCESS MORPHOMETRY IN ROUTINE KIDNEY BIOPSY SPECIMEN
Florian Siegerist, Greifswald, Germany

DIALYSIS PATTERNS: WHAT'S NEW?

Free Communication Session 24 — Hall New York - 17:00-18:30 (CEST)

Chairs: *Nada Dimkovic, Belgrade, Serbia*
Mario Cozzolino, Milan, Italy

Free communications

Mo26
THREE VERSUS TWICE-WEEKLY HEMODIALYSIS SESSIONS: A COMMUNITY EXPERIENCE.
Paavan Bonagiri, Charlottesville, VA, United States of America

Mo295
INCREASED VASCULAR REFILLING BY FEEDBACK-CONTROLLED ULTRAFILTRATION PROFILE
Susanne Kron, Berlin, Germany

Mo1029
EFFICACY OF EXPANDED HEMODIALYSIS AT DIFFERENT DIALYSATE FLOWS
Alejandra Molano-Triviño, Bogotá, Colombia

Mo1377
THE EFFECT OF INCREMENTAL START OF HAEMODIALYSIS ON BLOOD PRESSURE AND INTERDIALYTIC WEIGHT GAIN: PRELIMINARY FINDINGS FROM THE ENDURE STUDY
Adil Hazara, Hull, United Kingdom

Mo1643
INTERMITTENT HEMODIALYSIS WITHOUT ANTICOAGULATION
Silvius Frimmel, Rostock, Germany

VOLUME AND BLOOD PRESSURE CONTROL IN DIALYSIS

Symposium 5.4 Virtual Hall 1 - 17:00-18:30 (CEST)

Chairs: *Francesco Locatelli, Lecco, Italy*
Pantelis Sarafidis, Thessaloniki, Greece

1. The dialysis prescription for optimal volume control: a KDIGO report
Jennifer Flythe, Chapel Hill, NC, United States of America

2. The timing of Intradialytic hypotension
David Keane, Leeds, United Kingdom

3. Intradialytic hypertension: an ignored killer?
Pantelis Sarafidis, Thessaloniki, Greece

TRANSPLANTATION: RISKS & COMPLICATIONS

Free Communication Session 31 + Mini Lectures Virtual Hall 2 - 17:00-18:30 (CEST)

Chairs: *Luigi Biancone, Turin, Italy*
Daniel Abramowicz, Edegem, Belgium

Mini Lecture

Kidney transplant suitability for patients with prior cancers: what the nephrologist should know?
Alicja Debska-Slizien, Gdansk, Poland

Free communications

Mo146
DIURETIC USE IS ASSOCIATED WITH INCREASED RISK FOR POSTTRANSPLANTATION DIABETES MELLITUS IN RENAL TRANSPLANT RECIPIENTS
Sara Sokooti Oskooei, Groningen, Netherlands

Mo312
BONE DENSITOMETRY IN RENAL TRANSPLANTED PATIENTS
Ana Carina Ferreira, Lisboa, Portugal

Mo908
PATTERNS OF RENAL OSTEODYSTROPHY ONE YEAR AFTER KIDNEY TRANSPLANTATION
Hanne Skou Jørgensen, Aarhus, Denmark

Mo1651
RENAL TRANSPLANTATION MITIGATES INCREASED BIOLOGICAL (EPIGENETIC) AGE IN CHRONIC KIDNEY DISEASE
Ognian Neytchev, Glasgow, United Kingdom

era edta
LEADING EUROPEAN NEPHROLOGY

ERA-EDTA publishes internationally renowned scientific and educational journals

Stay updated to give the best possible care to your patients





Editor in Chief: *Denis Fouque, France*
academic.oup.com/ndt
Hybrid monthly journal - **Impact Factor: 4.531**

Editor in Chief: *Alberto Ortiz, Spain*
academic.oup.com/ckj
Open access bimonthly journal - **Impact Factor: 3.338**

What are the benefits of publishing in our journals?

- Fast average review time to first decision of 15 days
- Author videos and graphical abstracts for selected papers
- All figures are redesigned by professional medical illustrator
- Accepted manuscripts are published online within 48h after author licence has been signed
- Broad and efficient social media presence
- CKJ Journal Club e-seminars
- ERA-EDTA Members receive discount for open access publication

Day at a glance Tuesday, 08 June 2021

TREATMENT & OUTCOME OF GLOMERULONEPHRITIS page 64
ONCONEPHROLOGY page 64

RECENT ADVANCES IN KIDNEY TRANSPLANTATION: FOCUS ON IMMUNITY page 65
AN INTEGRATED VIEW OF ADTKD, AN EMERGING CLINICAL AND GENETIC ENTITY page 65
NON-DIALYSING IN THE 21ST CENTURY page 65

A NEW LOOK AT TUBULAR FUNCTIONS page 66
AKI IN SPECIAL SITUATIONS page 66
DIABETIC NEPHROPATHY 2021 page 66

URAEMIC TOXICITIES page 67
PROTECT THE MEMBRANE page 67

PLANERY LECTURE 3 page 68
NEPHROLOGY PEARLS page 68

Scientific Programme

TREATMENT & OUTCOME OF GLOMERULONEPHRITIS

Free Communication Session 11 + Mini Lectures — Hall A1 - 08:30-10:00 (CEST)

Chairs: *Manuel Praga, Pozuelo de Alarcón, Spain*
Marion Haubitz, Fulda, Germany

Mini Lecture

C3 Glomerulopathy and Membranoproliferative Glomerulonephritis: different diseases same treatment?
Marina Noris, Milan, Italy

Free communications

Tu1034
INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY
Jonathan Barratt, Leicester, United Kingdom

★ Tu1505
RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY. A MULTICENTRE STUDY
Giorgio Trivioli, Florence, Italy

Tu1834
NEUTROPHILS PLAY A KEY ROLE ON THE INITIATION OF GLOMERULAR HEMATURIA IN A POSTINFECTIOUS IGAN EXPERIMENTAL MODEL
Carmen Herencia, Madrid, Spain

Tu1907
CRESCENTS DERIVE FROM SINGLE PODOCYTE PROGENITORS AND A DRUG ENHANCING THEIR DIFFERENTIATION ATTENUATES RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS.
Maria Elena Melica, Florence, Italy

ONCONEPHROLOGY

Symposium 3.4 — Hall A3-7 (Plenary) - 08:30-10:00 (CEST)

Chairs: *Camillo Porta, Pavia, Italy*
Mariadelina Simeoni, Naples, Italy

1. High cut-off filters and multiple myeloma
Paul Cockwell, Birmingham, United Kingdom

2. Cancer immunotherapies (checkpoint inhibitors, CAR-T cells, IL-2) and the kidney
Laura Cosmai, Pavia, Italy

3. Haemathological disorders in transplant recipients
Jolanta Malyszko, Warsaw, Poland

Scientific Programme

RECENT ADVANCES IN KIDNEY TRANSPLANTATION: FOCUS ON IMMUNITY

Symposium 7.2 — Hall A8 - 08:30-10:00 (CEST)

Chairs: *Dany Anglicheau, Paris, France*
Martin de Borst, Groningen, Netherlands

1. NON-HLA Incompatibilities: what's new
Rainer Oberbauer, Vienna, Austria

2. Targeting immuno-inflammation in kidney transplantation: a new weapon against organ fibrosis
Gianluigi Zaza, Verona, Italy

3. Immunologic monitoring and biomarkers in kidney transplant recipients
Chan-Duck Kim, Daegu, Korea, Rep. of South

AN INTEGRATED VIEW OF ADTKD, AN EMERGING CLINICAL AND GENETIC ENTITY

Symposium 2.6 — Hall Budapest - 08:30-10:00 (CEST)

Chairs: *Nine Knoers, Groningen, Netherlands*
Albertien van Eerde, Utrecht, Netherlands

1. Clinical and genetic spectra of ADTKD
Eric Olinger, Zurich, Switzerland

2. Cellular mechanisms, genotype to phenotype
Luca Rampoldi, Milan, Italy

3. ADTKD-MUC1 - from diagnostics to mechanisms
Stanislav Kmoch, Prague, Czech Republic

NON-DIALYSING IN THE 21ST CENTURY

Symposium 5.1 — Hall Dublin - 08:30-10:00 (CEST)

Chairs: *Mehmet Sever, Istanbul, Turkey*
Dimitrios Goumenos, Patras, Greece

1. Non-dialysis in ESRD: how to offer conservative care
Barbara C van Munster, Groningen, Netherlands

2. Dialysis comorbidities and outcome
Patrick Finne, Helsinki, Finland

3. End of life in ESKD: Complex decision interaction among the patient, the family and the nephrologist
Vanita Jassal, Toronto, Canada

Scientific Programme

A NEW LOOK AT TUBULAR FUNCTIONS

Symposium 1.2 — Hall Helsinki - 08:30-10:00 (CEST)

Chairs: *Dominique Eladari, Paris, France*
Pascal Houillier, Paris, France

1. Paracellular transport via claudins is essential for normal kidney function
Markus Bleich, Kiel, Germany

2. Inherited defects of the proximal tubule reveal important pathways
Richard Warth, Regensburg, Germany

3. How to build a tubular epithelium?
Kai Schmidt-Ott, Berlin, Germany

AKI IN SPECIAL SITUATIONS

Symposium 9.1 — Hall London - 08:30-10:00 (CEST)

Chairs: *Christiane Erley, Berlin, Germany*
Casper Franssen, Groningen, Netherlands

1. AKI in oncology patients
Andrzej Wiecek, Katowice, Poland

2. COVID-19 and AKI
Javier A. Neyra, Lexington, KY, United States of America

3. AKI: a true risk or predictor of CKD?
Claudio Ronco, Vicenza, Italy

DIABETIC NEPHROPATHY 2021

Symposium 8.2 — Hall New York - 08:30-10:00 (CEST)

Chairs: *Katherine Tuttle, Spokane, WA, United States of America*
Francesco Trevisani, Milan, Italy

1. Nephroprotective antidiabetic drugs: a prescription algorithm
Clara Garcia Carro, Barcelona, Spain

2. Beyond antidiabetic drugs for DKD: what is new and upcoming
Beatriz Fernandez Fernandez, Madrid, Spain

3. How should future trials for DKD look like
Christoph Wanner, Würzburg, Germany

Scientific Programme

URAEMIC TOXICITIES

Symposium 4.3 — Virtual Hall 1 - 08:30-10:00 (CEST)

Chairs: *Griet Glorieux, Gent, Belgium*
Joachim Jankowski, Aachen, Germany

1. Uraemic toxins and endothelium
Andréa Emilia Marques Stinghen, Curitiba, Brazil

2. Uraemic toxins and macrophages
Lucie Henaut, Amiens, France

3. Uric acid and allopurinol in CKD: a paradigm change
Bjorn Meijers, Leuven, Belgium

PROTECT THE MEMBRANE

Free Communication Session 25 + Mini Lectures — Virtual Hall 2 - 08:30-10:00 (CEST)

Chairs: *Simon Davies, Stoke-on-Trent, United Kingdom*
Martin Kuhlmann, Berlin, Germany

Mini Lecture

Mistakes we make in treating peritonitis
Mark Lambie, Stoke-On-Trent, United Kingdom

Free communications

Tu110
MESENCHYMAL STEM CELL EXOSOMES AMELIORATE MICE PERITONEAL FIBROSIS INDUCED BY HUMAN PERITONITIS DIALYSIS EFFLUENT
Kehong Chen, Chongqing, China

Tu179
ASSOCIATION OF SINGLE AND SERIAL MEASURES OF SERUM PHOSPHORUS WITH ADVERSE OUTCOMES IN PATIENTS ON PERITONEAL DIALYSIS: RESULTS FROM THE INTERNATIONAL PDOPPS
Marcelo Lopes, Ann Arbor, MI, United States of America

Tu1022
PROTEOMIC PROFILE OF MESOTHELIAL EXOSOMES ISOLATED FROM PERITONEAL DIALYSIS EFFLUENT OF CHILDREN WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Edoardo La Porta, Rapallo, Italy

Tu2216
DECLINING PERITONEAL HOST DEFENCES REVEALED BY EX-VIVO CYTOKINE RELEASE ASSAY OF PERITONEAL DIALYSIS EFFLUENT CELLS
Rebecca Herzog, Vienna, Austria

Scientific Programme

PLANERY LECTURE 3

Hall A3-7 (Plenary) - 10:15-11:00 (CEST)

Chairs: *Annette Bruchfeld, Stockholm, Sweden*
Maria José Soler Romeo, Barcelona, Spain

Integrating multiomics data for a better understanding of kidney disease
Anna Köttgen, Freiburg, Germany

NEPHROLOGY PEARLS

Closing Session — Hall A3-7 (Plenary) - 11:15-12:45 (CEST)

Chairs: Roser Torra, Barcelona, Spain
Christoph Wanner, Würzburg, Germany

Basic Science and Translational Nephrology
Carsten Wagner, Zurich, Switzerland

Epidemiology and Clinical Nephrology
Kate Stevens, Glasgow, United Kingdom

ESKD and Dialysis
Rukshana Shroff, London, United Kingdom

Kidney Transplantation
Luuk Hilbrands, Nijmegen, Netherlands

See you next year

59TH
ERA-EDTA
CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022

Industry Sponsored Symposia

Day at a glance

Sunday 06 June 2021

PROTEINURIA TREATMENT TARGETS IN FSGS AND IGA NEPHROPATHY	page 70
DIAGNOSIS, GENETICS, AND PATHOPHYSIOLOGY OF ALPORT SYNDROME	page 71
UNDERSTANDING THE APOL1 CONNECTION IN PROTEINURIC KIDNEY DISEASE	page 72
HYPERKALAEMIA IN CKD: AN INTERACTIVE DISCUSSION ON CURRENT MANAGEMENT	page 73
A NEW PERSPECTIVE IN THE MANAGEMENT OF ATTP: THE NEPHROLOGIST APPROACH	page 74
RENAL DENERVATION -A DIFFERENT TOOL FOR HYPERTENSION CARE	page 75
MEMBRANE INNOVATION: FROM BENCH TO BEDSIDE	page 76
EXPERT CASE CHALLENGE SGLT2I IN CKD: HOW TO OVERCOME CLINICAL INERTIA?	page 77
CKD-MBD PATIENT MANAGEMENT – A CLINICAL PERSPECTIVE	page 78
HYPERKALAEMIA AND CKD: BEYOND POTASSIUM CONTROL	page 79
ADVANCES IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: IMPROVING PATIENT CARE TO SLOW DISEASE PROGRESSION	page 80
NONSTEROIDAL MRAS TO IMPROVE OUTCOMES IN PATIENTS WITH CKD AND T2D	page 81
A NEW APPROACH FOR GLOMERULONEPHRITIS: TARGETING THE ALTERNATIVE COMPLEMENT PATHWAY	page 82
IGA NEPHROPATHY - CAN WE IMPROVE TREATMENT OPTIONS FOR PATIENTS?	page 83
WHAT'S NEXT FOR PATIENTS WITH LUPUS NEPHRITIS?	page 84
FRONTIERS IN THE MANAGEMENT OF AHUS	page 85
ANAEMIA OF CKD: CHALLENGING THE STATUS QUO	page 86

Industry Sponsored Symposia

PROTEINURIA TREATMENT TARGETS IN FSGS AND IGA NEPHROPATHY

Sunday, June 6, 2021 | Hall Dublin - 09:45-10:45 (CEST)

Chair: *Marcus Moeller, Aachen, Germany*

Introduction and setting the scene
Marcus Moeller, Aachen, Germany

Proteinuria targets in FSGS
Loreto Gesualdo, Bari, Italy

Proteinuria targets in IgA Nephropathy
Frederick Tam, London, United Kingdom

Proteinuria as an innovative endpoint: A multi-stakeholder effort
Marcus Moeller, Aachen, Germany

Close
Marcus Moeller, Aachen, Germany

Organised by TRAVERE THERAPEUTICS

Industry Sponsored Symposia

DIAGNOSIS, GENETICS, AND PATHOPHYSIOLOGY OF ALPORT SYNDROME

Sunday, June 6, 2021 — Hall Helsinki - 09:45-10:45 (CEST)

Chair: *Monica Furlano, Barcelona, Spain*

Diagnosis of Alport syndrome
Monica Furlano, Barcelona, Spain

Classification of Alport syndrome subtypes
Monica Furlano, Barcelona, Spain

Genetics underlying subtypes and prognosis
Monica Furlano, Barcelona, Spain

Chronic inflammation in Alport syndrome
Monica Furlano, Barcelona, Spain

Questions and Answers
Monica Furlano, Barcelona, Spain

Organised by REATA PHARMACECUTICALS, INC

Industry Sponsored Symposia

UNDERSTANDING THE APOL1 CONNECTION IN PROTEINURIC KIDNEY DISEASE

Sunday, June 6, 2021 Hall Budapest - 09:45-10:45 (CEST)

Chairs: Bertrand Knebelmann, Paris, France
Kate Bramham, London, United Kingdom

Introduction from Chairs
Bertrand Knebelmann, Paris, France
Kate Bramham, London, United Kingdom

APOL1-Mediated Nephropathy: Bench to Bedside
Martin Pollak, Boston, MA, United States of America

Discussion
Bertrand Knebelmann, Paris, France
Kate Bramham, London, United Kingdom
Martin Pollak, Boston, MA, United States of America
Aude Servais, Paris, France

Emerging Perspectives on Genotyping for APOL1 in Kidney Disease
Aude Servais, Paris, France

Discussion
Bertrand Knebelmann, Paris, France
Kate Bramham, London, United Kingdom
Martin Pollak, Boston, MA, United States of America
Aude Servais, Paris, France

Close from Chairs
All Faculty (Chairs and Presenters)

Organised by VERTEX PHARMACEUTICALS

VERTEX
THE SCIENCE of POSSIBILITY

Industry Sponsored Symposia

HYPERKALAEMIA IN CKD: AN INTERACTIVE DISCUSSION ON CURRENT MANAGEMENT

Sunday, June 6, 2021 — Hall New York - 09:45-10:45 (CEST)

Chairs: *Carol Pollock, Sydney, Australia*

Welcome & Introduction
Carol Pollock, Sydney, Australia

Recommendations for RAASi Optimisation
Kieran McCafferty, London, United Kingdom

Recommendations for dietary K+ intake - is it time for a change?
Carla Avesani, Stockholm, Sweden

Long-term Management of Hyperkalaemia, Including the Role of K+ Binders
Andrew Frankel, London, United Kingdom

Audience Q&A & Chair's Summary
All faculty, moderated by *Carol Pollock, Sydney, Australia*

Organised by ASTRAZENECA



Industry Sponsored Symposia

A NEW PERSPECTIVE IN THE MANAGEMENT OF ATTP: THE NEPHROLOGIST APPROACH

Sunday, June 6, 2021 Hall London - 09:45-10:45 (CEST)

Chair: *Paul Brinkkötter, Cologne, Germany*

Welcome and introduction
Paul Brinkkötter, Cologne, Germany

Diagnosing aTTP and its challenges
Ralph Wendt, Leipzig, Germany

Acute aTTP treatment - where do we stand in 2021?
François Provot, Lille, France

Experience through learning: clinical pearls
Paul Brinkkötter, Cologne, Germany

Q&A
All

Organised by SANOFI GENZYME

Industry Sponsored Symposia

RENAL DENERVATION -A DIFFERENT TOOL FOR HYPERTENSION CARE

Sunday, June 6, 2021 Hall A1 - 09:45-10:45 (CEST)

Chairs: *Peter J. Blankestijn, Utrecht, Netherlands*
Roland E. Schmieder, Erlangen, Germany

Latest Evidence on Renal Denervation
Konstantinos Tsioufis, Athens, Greece

Renal Denervation in Practice
Roland E. Schmieder, Erlangen, Germany

Should Renal Denervation be an Option for CKD Patients?
José Antonio García Donaire, Madrid, Spain

Q&A
Peter J. Blankestijn, Utrecht, Netherlands
Roland E. Schmieder, Erlangen, Germany

Organised by MEDTRONIC

Medtronic
Further, Together

Industry Sponsored Symposia

MEMBRANE INNOVATION: FROM BENCH TO BEDSIDE

Sunday, June 6, 2021 — Virtual Hall 1 - 09:45-10:45 (CEST)

Chair: *Andrew Davenport, London, United Kingdom*

Pivotal Attributes of Membrane Innovation
Martin K. Kuhlmann, Berlin, Germany

How can membrane innovation improve outcomes
Bernard Canaud, Montpellier, France

Q&A Session
All speakers and chair

Organised by FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Industry Sponsored Symposia

EXPERT CASE CHALLENGE SGLT2I IN CKD: HOW TO OVERCOME CLINICAL INERTIA?

Sunday, June 6, 2021 — Virtual Hall 2 - 09:45-10:45 (CEST)

Chair: *Christoph Wanner, Würzburg, Germany*

Nephrology Clinic - Introduction: A patient with type 2 Diabetes and Chronic Kidney Disease
Christoph Wanner, Würzburg, Germany

Question 1 - Diagnosis and Guidelines. What is the rationale for SGLT2i?
Janaka Karalliedde, London, United Kingdom

Question 2 - Initiating therapy. What are the practical challenges with SGLT2i therapy?
Alice Cheng, Toronto, Canada

Question 3 - Follow up. Defining treatment goals, a shift in paradigm?
Peter Rossing, Gentofte, Denmark

Expert Case Challenge, Answers and guidance to overcome clinical inertia
All faculty

Organised by PACE-CME: PHYSICIANS ACADEMY FOR CARDIOVASCULAR EDUCATION

Industry Sponsored Symposia

CKD-MBD PATIENT MANAGEMENT - A CLINICAL PERSPECTIVE

Sunday, June 6, 2021 Hall Dublin - 13:30-14:30 (CEST)

Chair: *Julia Weinmann-Menke, Mainz, Germany*

Chair's welcome and introduction
Julia Weinmann-Menke, Mainz, Germany

Practical approaches to SHPT management in non-dialysis CKD patients:
a case-based discussion
Michael Germain, Springfield, IL, United States of America

Addressing the clinical challenges of hyperphosphataemia management in CKD:
expert strategies to improve patient outcomes
Emilio Sanchez, Gijón, Spain

Live Q&A and closing remarks
All / Prof. Julia Weinmann-Menke, Mainz, Germany (Chair)

Organised by VIFOR PHARMA MANAGEMENT LTD.

Industry Sponsored Symposia

HYPERKALAEMIA AND CKD: BEYOND POTASSIUM CONTROL

Sunday, June 6, 2021 — Hall A8 - 13:30-14:30 (CEST)

Chair: *Michel Jadoul, Brussels, Belgium*

Welcome and introductions
Michel Jadoul, Brussels, Belgium

Facing the risk of chronic hyperkalaemia in CKD: can we do better?
Michel Jadoul, Brussels, Belgium

The elephant in the room: Is dietary potassium the main cause of hyperkalemia in CKD?
Juan-Jesus Carrero, Solna, Sweden

K+ control in CKD - time to think long-term
Patrick Rossignol, Vandoeuvre-lès-Nancy, France

Interactive panel discussion
Michel Jadoul, Brussels, Belgium

Organised by VIFOR PHARMA MANAGEMENT LTD.

VIFOR PHARMA

Industry Sponsored Symposia

ADVANCES IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: IMPROVING PATIENT CARE TO SLOW DISEASE PROGRESSION

Sunday, June 6, 2021 Hall Helsinki - 13:30-14:30 (CEST)

Chair: *Thomas Benzing, Cologne, Germany*

Welcome
Thomas Benzing, Cologne, Germany

Clinical practice update and case presentations in ADPKD
York Pei, Toronto, Canada

Dietary interventions in autosomal-dominant polycystic kidney disease
Thomas Weimbs, Santa Barbara, CA, United States of America

Q&A (Live)
All

Organised by SANOFI GENZYME

Industry Sponsored Symposia

NONSTEROIDAL MRAS TO IMPROVE OUTCOMES IN PATIENTS WITH CKD AND T2D

Sunday, June 6, 2021 Hall Budapest - 13:30-14:30 (CEST)

Chair: *María José Soler, Barcelona, Spain*

Welcome & Introduction
María José Soler, Barcelona, Spain

Inflammation and fibrosis: An overlooked driver of CKD progression in T2D?
Katherine Tuttle, Spokane, WA, United States of America

The FIDELIO-DKD trial: New insights on the benefits of MR antagonism
Rajiv Agarwal, Indianapolis, IN, United States of America

From the trial to the clinic: Applying the evidence to everyday practice
Pantelis Sarafidis, Thessaloniki, Greece

Q&A and Close
All Faculty and María José Soler, Barcelona, Spain

Organised by BAYER AG

Industry Sponsored Symposia

A NEW APPROACH FOR GLOMERULONEPHRITIS: TARGETING THE ALTERNATIVE COMPLEMENT PATHWAY

Sunday, June 6, 2021 Hall New York - 13:30-14:30 (CEST)

Chair: *David Kavanagh, Newcastle upon Tyne, United Kingdom*

Welcome and introduction
David Kavanagh, Newcastle upon Tyne, United Kingdom

The role of complement in glomerulonephritis
Peter Zipfel, Jena, Germany

Towards a targeted therapy in complement-driven renal disease: a program overview
Matthias Meier, Basel, Switzerland

C3 glomerulopathy: new treatment perspectives
Manuel Praga, Madrid, Spain

IgA nephropathy: novel therapeutic approaches
Jonathan Barratt, Leicester, United Kingdom

Q&A
All faculty

Organised by NOVARTIS PHARMA AG

Industry Sponsored Symposia

IGA NEPHROPATHY - CAN WE IMPROVE TREATMENT OPTIONS FOR PATIENTS?

Sunday, June 6, 2021 Hall London - 13:30-14:30 (CEST)

Chair: *Richard Lafayette, Palo Alto, CA, United States of America*

Welcome & Introduction
Richard Lafayette, Palo Alto, CA, United States of America

KDIGO clinical practice guidelines for glomerulonephritis: 2021 update
Heather Reich, Toronto, Canada

The therapeutic challenges of IgAN in 2021
Jonathan Barratt, Leicester, United Kingdom

How are we addressing the unmet medical needs of patients with IgAN?
Brad Rovin, Columbus, OH, United States of America

Q&A
Richard Lafayette, Palo Alto, CA, United States of America

Organised by CALLIDITAS THERAPEUTICS AB

calliditas THERAPEUTICS

Industry Sponsored Symposia

WHAT'S NEXT FOR PATIENTS WITH LUPUS NEPHRITIS?

Sunday, June 6, 2021 — Hall A1 - 13:30-14:30 (CEST)

Chair: *Onno Teng, Leiden, Netherlands*

Welcome and introductory presentation
Onno Teng, Leiden, Netherlands

Treatment goals, targets and guidelines
Liz Lightstone, London, United Kingdom

What's next?
Hans-Joachim Anders, Munich, Germany

Panel discussion and summary
Onno Teng, Leiden, Netherlands
Liz Lightstone, London, United Kingdom
Hans-Joachim Anders, Munich, Germany

Organised by GLAXOSMITHKLINE

Industry Sponsored Symposia

FRONTIERS IN THE MANAGEMENT OF AHUS

Sunday, June 6, 2021 — Virtual Hall 1 - 13:30-14:30 (CEST)

Chair: *Hermann Haller, Hannover, Germany*

Complement C5 at the heart of aHUS
Hermann Haller, Hannover, Germany

C5 inhibition in aHUS, from clinical trials to practical use
Anja Gäckler, Essen, Germany

aHUS and kidney transplant, a particular challenge
Yahsou Delmas, Bordeaux, France

Panel Discussion / Q&A All faculty
All Faculty

Organised by ALEXION PHARMACUTICALS, INC.



Industry Sponsored Symposia

ANAEMIA OF CKD: CHALLENGING THE STATUS QUO

Sunday, June 6, 2021 Virtual Hall 2 - 13:30-14:30 (CEST)

Chair: *Danilo Fliser, Homburg, Germany*

Welcome & Introduction
Danilo Fliser, Homburg, Germany

Should anaemia of CKD be more of a priority for nephrologists?
David Wheeler, London, United Kingdom

Anaemia of CKD pathophysiology: What are the mechanisms?
Patrick Maxwell, Cambridge, United Kingdom

Clinical guidelines for anaemia of CKD: Are there any challenges?
Jan Galle, Lüdenscheid, Germany

Moderated audience Q&A
Danilo Fliser, Homburg, Germany

Organised by ASTELLAS PHARMA EUROPE LTD

Day at a glance Monday 07 June 2021

TARGETING CKD PATIENTS' QUALITY OF LIFE page 88

WHEN DELAYS COULD LEAD TO ESKD. IDENTIFYING AND MANAGING PRIMARY HYPEROXALURIA IN CLINICAL PRACTICE page 89

GLP-1RA IN DKD: A NEW PREVENTIVE CHALLENGE page 90

ETELCALCETIDE IN CLINICAL PRACTICE: MORE THAN JUST PTH? page 91

GLYCATED ALBUMIN: A TOOL AT CLINICIANS' HAND IN MANAGING DIABETIC NEPHROPATHY page 92

STRIKING THE RIGHT BALANCE IN ANCA-ASSOCIATED VASCULITIS (AAV) page 93

20 YEARS OF REAL-WORLD EVIDENCE DATA FOR FABRY DISEASE page 94

ADDRESSING GAPS IN PATIENT CARE IN RARE INHERITED DISORDERS: THE ROLE OF THE NEPHROLOGIST page 95

RENAISSANCE OF PATIENT HEMODIALYSIS - NOVEL PMMA MEMBRANE FOR DIVERSIFIED HEMODIALYSIS page 96

CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS (CKD-AP): ADDRESSING UNMET NEEDS IN PATIENTS ON DIALYSIS page 97

IDEFIRIX - A PARADIGM SHIFT IN TRANSPLANTING THE UNTRANSPLANTABLE? page 98

SGLT2 INHIBITORS: A PRACTICAL GUIDE page 99

CHOOSING THE RIGHT: THERAPY, PLACE AND TIME INTEGRATING PATIENT PERSPECTIVES AND PATIENT REPORTED OUTCOMES INTO CLINICAL PRACTICE page 100

GLP-1 RECEPTOR AGONISTS AND THE KIDNEY page 101

Industry Sponsored Symposia

TARGETING CKD PATIENTS' QUALITY OF LIFE

Monday, June 7, 2021 — Hall New York - 09:45-10:45 (CEST)

Chair: *Giorgina Piccoli, Le Mans, France*

Welcome and introduction
Giorgina Piccoli, Le Mans, France

Living Well with Kidney Disease - Importance of patients' empowerment
Kamyar Kalantar-Zadeh, Orange, CA, United States of America

Tailored nutritional approach to improve adherence and QoL in CKD patients
Giorgina Piccoli, Le Mans, France

KDOQI guideline 2020 recommendations for nutrition in CKD - Practical considerations
Denis Fouque, Pierre-Bénite, France

2020 Award winning research project presentation: Effects of Keto-Analogues supplementation on Quality of Life in Palliative Care of ESKD Patients
Paramat Thimachai, Bangkok, Thailand

Panel discussion
All faculty

Organised by FRESENIUS KABI

FRESENIUS KABI
caring for life

Industry Sponsored Symposia

WHEN DELAYS COULD LEAD TO ESKD. IDENTIFYING AND MANAGING PRIMARY HYPEROXALURIA IN CLINICAL PRACTICE

Monday, June 7, 2021 Hall London - 09:45-10:45 (CEST)

Chair: *Felix Knauf, Berlin, Germany*

Welcome & introduction
Felix Knauf, Berlin, Germany

The clock is ticking: When and how to evaluate a referral for potential hyperoxaluria
Rezan Topaloglu, Ankara, Turkey

Reducing oxalate to reduce the risk of ESKD
Felix Knauf, Berlin, Germany

RNAi Therapeutics: A new approach to managing primary hyperoxaluria
Daniel Fuster, Bern, Switzerland

Questions & answers

Organised by ALNYLAM PHARMACEUTICALS



Disclaimer:
For Healthcare Professionals only. This meeting is not intended for UK Healthcare Professionals.
Sponsored and funded by Alnylam Pharmaceuticals.
Oxlumo® is commercially available in Germany, and relevant pricing and reimbursement approval is pending in other EU countries. Full prescribing information for Oxlumo® can be accessed here: https://www.ema.europa.eu/en/documents/product-information/oxlumo-epar-product-information_en.pdf. Registration conditions differ internationally; please refer to your local prescribing information for further information.
To report adverse events please refer to your local reporting guidelines. April 2021 | OXL-CEMEA-00048

Industry Sponsored Symposia

GLP-1RA IN DKD: A NEW PREVENTIVE CHALLENGE

Monday, June 7, 2021 Hall A1 - 09:45-10:45 (CEST)

Chair: *Johannes Mann, Munich, Germany*

Nephrology Clinic - Introduction: A patient with type 2 Diabetes and Chronic Kidney Disease
Johannes Mann, Munich, Germany

What are the preventive challenges for a nephrologist?
Ofri Mosenzon, Hadassah, Israel

How can GLP-1RA benefit a patient with diabetes and CKD?
Daniël van Raalte, Amsterdam, Netherlands

Where do GLP-1RA fit in in current and future management?
Frederik Persson, Copenhagen, Denmark

Interactive discussion: Defining a strategy for prevention of T2DM & CKD
All faculty

Organised by PACE-CME: PHYSICIANS ACADEMY FOR CARDIOVASCULAR EDUCATION

Industry Sponsored Symposia

ETELCALCETIDE IN CLINICAL PRACTICE: MORE THAN JUST PTH?

Monday, June 7, 2021 — Virtual Hall 1 - 09:45-10:45 (CEST)

Chair: *Christiane Erley, Berlin, Germany*

Welcome and introduction
Christiane Erley, Berlin, Germany

FGF23 in CKD-MBD: a scientific update
Marc Vervloet, Amsterdam, Netherlands

Calcimimetics in clinical practice: Management of sHPT with etelcacetide and impact on cardiovascular outcomes
Rainer Oberbauer, Vienna, Austria

Panel discussion
Christiane Erley, Berlin, Germany
Marc Vervloet, Amsterdam, Netherlands
Rainer Oberbauer, Vienna, Austria

Closing remarks
Christiane Erley, Berlin, Germany

Organised by AMGEN

Industry Sponsored Symposia

GLYCATED ALBUMIN: A TOOL AT CLINICIANS' HAND IN MANAGING DIABETIC NEPHROPATHY

Monday, June 7, 2021 Virtual Hall 2 - 09:45-10:45 (CEST)

Chair: *Loreto Gesualdo, Bari, Italy*

Welcome & Introduction
Loreto Gesualdo, Bari, Italy

Current clinical practice in the management of Diabetic Kidney Disease
Barry I. Freedman, Winston-Salem, NC, United States of America

Importance of Best Practice Guidelines for Dialysis therapy as a tool for improving care of Diabetic Nephropaty patients
Masanori Abe, Tokyo, Japan

Personalized Medicine approaches in Diabetic Kidney Disease
Paola Pontrelli, Bari, Italy

Q&A live session

Organised by WERFEN AND ASAHI-KASEI PHARMA

AsahiKASEI
ASAHI KASEI PHARMA

Werfen
Diagnostic Solutions for Life

Industry Sponsored Symposia

STRIKING THE RIGHT BALANCE IN ANCA-ASSOCIATED VASCULITIS (AAV)

Monday, June 7, 2021 — Hall Dublin - 13:30-14:30 (CEST)

Chair: *Markus Ketteler, Stuttgart, Germany*

Welcome and Introductions
Markus Ketteler, Stuttgart, Germany

Remission and relapse in ANCA-associated vasculitis - what is the reality?
Andreas Kronbichler, Innsbruck, Austria

The short and long of glucocorticoids in ANCA-associated vasculitis
Lorraine Harper, Birmingham, United Kingdom

Q&A Concluding remarks
Markus Ketteler, Stuttgart, Germany

Organised by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

VIFOR PHARMA

Industry Sponsored Symposia

20 YEARS OF REAL-WORLD EVIDENCE DATA FOR FABRY DISEASE

Monday, June 7, 2021 Hall A8 - 13:30-14:30 (CEST)

Chair: *Sima Canaan-Kühl, Berlin, Germany*

Welcome
Sima Canaan-Kühl, Berlin, Germany

Optimization of fabry disease patients management after more than 20 years of clinical experience
Camilla Tøndel, Bergen, Norway

Lessons learned after two decades of fabry disease treatment
Alberto Ortiz, Madrid, Spain

Q&A (Live)
All

Organised by SANOFI GENZYME

SANOFI GENZYME

Industry Sponsored Symposia

ADDRESSING GAPS IN PATIENT CARE IN RARE INHERITED DISORDERS: THE ROLE OF THE NEPHROLOGIST

Monday, June 7, 2021 — Hall Helsinki - 13:30-14:30 (CEST)

Chairs: *Christoph Wanner, Würzburg, Germany*

Welcome & Introduction
Christoph Wanner, Würzburg, Germany

Transition from pediatric to adult care
David Cassiman, Leuven, Belgium

Managing multidisciplinary care in adult cystinosis patients
Aude Servais, Paris, France

The role of the nephrologist in Fabry care: from early diagnosis to therapeutic goals
Christine Kurschat, Cologne, Germany

Closure
Christoph Wanner, Würzburg, Germany

Organised by CHIESI FARMACEUTICI S.P.A.

Chiesi
Global Rare Diseases

Industry Sponsored Symposia

RENAISSANCE OF PATIENT HEMODIALYSIS - NOVEL PMMA MEMBRANE FOR DIVERSIFIED HEMODIALYSIS

Monday, June 7, 2021 Hall Budapest - 13:30-14:30 (CEST)

Chair: *Giuseppe Grandaliano, Rome, Italia*

Importance to remove HMW protein: why and how?
Laurent Juillard, Lyon, France

Role of a novel PMMA membrane in Patient-centered dialysis care
Ikuto Masakane, Yamagata, Japan

Immunomodulation in CKD-HD and waiting transplant list patient: role of PMMA
Giuseppe Grandaliano, Rome, Italy

Discussion
All Chairman and Speakers as above.

Organised by TORAY MEDICAL CO., LTD.

Industry Sponsored Symposia

CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS (CKD-AP): ADDRESSING UNMET NEEDS IN PATIENTS ON DIALYSIS

Monday, June 7, 2021 Hall New York - 13:30-14:30 (CEST)

Chair: *Gert Mayer, Innsbruck, Austria*

Chair's welcome and introduction
Gert Mayer, Innsbruck, Austria

Understanding the burden of CKD-associated pruritus
James Burton, Leicester, United Kingdom

Unravelling the pathophysiology of CKD-associated pruritus
Andreas Kremer, Erlangen, Germany

Clinical management of CKD-associated pruritus: current treatment options and future approaches
Steven Fishbane, Hempstead, NY, United States of America

Panel discussion, audience Q&A and close
All speakers as listed above

Organised by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD.

VIFOR PHARMA

Industry Sponsored Symposia

IDEFIRIX - A PARADIGM SHIFT IN TRANSPLANTING THE UNTRANSPLANTABLE?

Monday, June 7, 2021 Hall London - 13:30-14:30 (CEST)

Chair: *Uwe Heeman, Munich, Germany*

Welcome and Opening
Uwe Heeman, Munich, Germany

Defining the untransplantable
Christian Morath, Heidelberg, Germany

Pathways to transplant of the positive cross-match highly sensitised patients
Rainer Oberbauer, Vienna, Austria

Idefirix - A new treatment option
Tomas Lorant, Uppsala, Sweden

Discussion / Q&A

Organised by HANSA BIOPHARMA

Industry Sponsored Symposia

SGLT2 INHIBITORS: A PRACTICAL GUIDE

Monday, June 7, 2021 Hall A1 - 13:30-14:30 (CEST)

Chairs: *Hiddo Lambers Heerspink, Groningen, Netherlands*
Adeera Levin, Vancouver, Canada

Welcome & Introduction
Adeera Levin, Vancouver, Canada
Hiddo Lambers Heerspink, Groningen, Netherlands

From evidence to patient - when, why and how to initiate SGLT2 inhibitors in CKD
Meg Jardine, Sydney, Australia
Hiddo Lambers Heerspink, Groningen, Netherlands
Adeera Levin, Vancouver, Canada
Patrick Mark, Glasgow, United Kingdom

Audience Q&A
All Faculty

Supported by an unrestricted educational grant from ASTRAZENECA
and endorsed by UNIVERSITY MEDICAL CENTRE GRONINGEN



Industry Sponsored Symposia

CHOOSING THE RIGHT: THERAPY, PLACE AND TIME INTEGRATING PATIENT PERSPECTIVES AND PATIENT REPORTED OUTCOMES INTO CLINICAL PRACTICE

Monday, June 7, 2021 Virtual Hall 1 - 13:30-14:30 (CEST)

Chair: *Kitty J. Jaeger, Amsterdam, Netherlands*

Welcome & Introduction
Kitty J. Jaeger, Amsterdam, Netherlands

Peritoneal dialysis
Wim Van Biesen, Ghent, Belgium

Home hemodialysis
Natalie Borman, Portsmouth, United Kingdom

In-center Hemodialysis
Peter J. Blankestijn, Utrecht, Netherlands

Q&A
All speakers and chair

Organised by FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Industry Sponsored Symposia

GLP-1 RECEPTOR AGONISTS AND THE KIDNEY

Monday, June 7, 2021 Virtual Hall 2 - 13:30-14:30 (CEST)

Chair: *Peter Rossing, Gentofte, Denmark*

Brief introduction to symposium, objectives, sessions and speakers
Peter Rossing, Gentofte, Denmark

Chronic Kidney Disease in Type 2 Diabetes: what do we know?
Roland Schmieder, Erlangen, Germany

Kidney Outcomes with GLP1-RAs: what evidence have we seen so far?
Ofri Mosenzon, Hadassah, Israel

GLP-1RAs and the Kidney: what might the mechanism(s) of action be?
Hiddo Lambers Heerspink, Groningen, Netherlands

Panel Discussion
Chair and all speakers

Organised by NOVO NORDISK A/S



era edta
LEADING EUROPEAN NEPHROLOGY

Schedule your scientific and educational agenda **SAVE THE DATES**

See you in Paris in 2022

at the
"Paris Expo Porte de Versailles"
Congress Centre

59TH ERA-EDTA CONGRESS
PARIS & VIRTUAL
MAY 19-22, 2022

See you in Milan in 2023

at the
"MiCo"
Congress Centre

60TH ERA-EDTA CONGRESS
MILAN & VIRTUAL
JUNE 15-18, 2023

TRAVERE THERAPEUTICS

Travere Therapeutics-sponsored symposium at the 58th ERA-EDTA congress, 5–8 June 2021

58th ERA-EDTA CONGRESS FULLY VIRTUAL JUNE 5-8, 2021

JOIN OUR SPEAKERS TO HEAR ABOUT THE CLINICAL SIGNIFICANCE OF PROTEINURIA IN RELATION TO FSGS AND IgA NEPHROPATHY

Proteinuria treatment targets in FSGS and IgA nephropathy

Symposium and live Q&A

Sunday 6th June 2021, 09:45–10:45 CEST

(Available on demand thereafter on ERA-EDTA website)

Speakers



Dr. Marcus Moeller
RWTH Aachen University, Germany (Chair)



Prof. Frederick Tam
Imperial College London, UK



Prof. Loreto Gesualdo
Università degli Studi di Bari Aldo Moro, Italy

Agenda:

Introduction
Dr. Marcus Moeller

Proteinuria targets in FSGS
Prof. Loreto Gesualdo

Proteinuria targets in IgA nephropathy
Prof. Frederick Tam

Proteinuria as an innovative endpoint: A multi-stakeholder effort
Dr. Marcus Moeller

Audience Q&A and close
Moderated by Dr. Marcus Moeller



© 2021 Travere Therapeutics, Inc.
All rights reserved. April 2021 - MA-417
The ERA-EDTA assumes no responsibility for the information published in this document.

era edta
LEADING EUROPEAN NEPHROLOGY

59TH

ERA-EDTA CONGRESS

PARIS & VIRTUAL

MAY 19-22, 2022



SAVE THE DATE

The ERA-EDTA Congress offers you the chance to actively contribute to the future of Nephrology, leading Science, Education and Networking.

We look forward to meeting you in 2022!